
Fig. 1

		Position 57		Position 67	
DQ		Nucleotide	Amino Acid	Nucleotide	Amino Acid
	DQB1*0201	GCC	Α	ATC	I
	DQB1*03011	GAC	D	GTC	V
	DQB1*03012	GAC	D	GTC	V
	DQB1*0302	GCC	Α	GTC	V
	DQB1*03032	GAC	D	GTC	V
	DQB1*03033	GAC	D	GTC	V
	DQB1*0401	GAC	D	ATC	1
	DQB1*0402	GAC	D	ATC	1
	DQB1*0501	GTT	V	GTC	V
	DQB1*0502	AGC	S	GTC	V
	DQB1*05031	GAC	D	GTC	V
	DQB1*05032	GAT	D	GTC	V
	DQB1*06011	GAC	D	ATC	1
	DQB1*06012	GAC	D	ATC	ı
	DQB1*06013	GAC	D	ATC	1
	DQB1*0602	GAT	D	GTC	V
	DQB1*0603	GAT	D	GTC	V
	DQB1*06041	GTT	V	GTC	V
	DQB1*06042	GTT	V	GTC	V
	DQB1*06051	GTT	V	GTC	V
	DQB1*06052	GTT	V	GTC	V


DRB1*0801	AGC	S	TTC	F
DRB1*08021	GAT	D	TTC	F
DRB1*08022	GAT	D	TTC	F
DRB1*0803	AGC	S	ATC	
DRB1*08041	GAT	D	TTC	F
DRB1*08042	GAT	D	TTC	F
DRB1*08043	GAT	D	TTC	F
DRB1*09012	GTC	V	TTC	F
DRB1*10011	GAT	D	CTC	L
DRB1*10012	GAT	D	CTC	L
DRB1*111011	GAT	D	TTC	F
DRB1*111012	GAT	D	TTC	F
DRB1*111013	GAT	D	TTC	F
DRB1*11102	GAT	D	ATC	ı
DRB1*11103	GAT	D	TTC	F
DRB1*111041	GAT	D	TTC	F
DRB1*111042	GAT	D	TTC	F
DRB1*1201	GTC	V	ATC	1
DRB1*12021	GTC	V	TTC	F
DRB1*12022	GTC	V	TTC	F
DRB1*1301	GAT	D	ATC	
DRB1*13021	GAT	D	ATC	
DRB1*13022	GAT	D	ATC	

DRB1*1303	AGC	S	ATC	
DRB1*1304	AGC	S	ATC	I
DRB1*1305	GAT	D	TTC	F
DRB1*14011	GCT	Α	CTC	L
DRB1*14012	GCT	Α	CTC	L
DRB1*1402	GAT	D	CTC	L
DRB1*1403	GAT	D	CTC	L
DRB1*1404	GCT	Α	CTC	L
DRB1*1405	GAT	D	CTC	L
DRB1*1406	GAT	D	CTC	L
DRB1*1407	GCT	Α	CTC	L
DRB1*1408	GAT	D	CTC	L
DRB1*15011	GAC	D	TTC	F
DRB1*15012	GAC	D	TTC	F
DRB1*15021	GAC	D	ATC	1
DRB1*15022	GCC	D	ATC	1
DRB1*15023	GAC	D	ATC	ı
DRB1*16011	GAC	D	TTC	F
DRB1*16012	GAC	D	TTC	F
DRB1*16021	GAC	D	CTC	L
DRB1*16022	GAC	D	CTC	L

DQB1*050301(1)




DQB1*050301(2)




DQB1*050301(3)






DR57D-1

Stomach cancer resection only




DR57D-2

Chemotherapy




DR57D-3

Immunotherapy




DR67I-1

Stomach cancer resection only




DR67I-2 Chemotherapy



DR67I-3

Immunotherapy



DR67I,F,L-1


Stomach cancer resection only

 d + DR67I(-)/


c + DR67I(+)/

b + DR67I(+)/F(+)


a + DR67I(+)/L(+)



DR67I,F,L-2




DR67I,F,L-3




DR57D-DR67I-1

Stomach cancer resection only



DR57D-DR67I-2



DR57D-DR67I-3

Immunotherapy

a + DR57D(+)/67K+)





Fig. 19






Fig. 20








Fig. 21













Chemotherapy





No Adjuvant Therapy









































Fig. 41

5-year Survival Comparison

	DR			DQ			DP	
%	APR_25 = RR	0.8333						
			*	AQP_21 = GG	0.8782			
%	ARP_17 = AA	0.8333						
%	ARP_16 = VV	0.8333	*	AQP_6 = TT	0.8782			
%	ARP10 = YY	0.7684	*	AQP_4 = VV	0.8782			
*	ARP11 = DS	0.8394	%@	AQP3 = SS	0.7644			
*	ARP13 = GH	0.8375	%	AQP23 = LR	0.7789			
*	ARP26 = FL	0.7981	%	AQP30 = HH	0.8247			
%	ARP32 = HH	0.8228	%@	AQP37 = YY	0.7661			
			%	AQP53 = LL	0.7965		APP55 = AD	0.8095
@	ARP57 = AV	1	%	AQP56 = LP	0.7847	%	APP65 = IL	0.8618
%	ARP67 = FF	0.9444	%	AQP66 = DE	0.7786	%	APP69 = EK	0.7985
*	ARP67 = IL	0.8106	%*	AQP66 = EE	0.7535			
%	ARP73 = AA	0.7554	%	AQP67 = IV	0.7786			-
%	ARP78 = VV	0.9	%	AQP74 = ES	0.799			
%	ARP86 = VV	0.8618	%@	AQP75 = LV	0.7963			
%	ARP96 = HY	0.9	%	AQP84 = QQ	0.7965	%	APP178 = LM	0.8261
*	ARP96 = HY	0.79	%	AQP85 = LL	0.7965			
%	ARP98 = EK	0.7846	*	AQP87 = FY	0.7922			
%	ARP104 = AA	0.8355	%	AQP89 = TT	0.7965			
%@	ARP133 = RR	0.7774	%	AQP90 = TT	0.7965			
%@	ARP142 = VV	0.7774	%	AQP125 = GS	0.8179	······		
%	ARP189 = RR	0.7328	%	AQP140 = TT	0.7957			
			%	AQP182 = NN	0.7957			<u> </u>
			%	AQP185 = II	0.8136			
			%@	AQP197 = SS	0.7644			
			%	AQP220 = HH	0.7965			
			%	AQP221 = HH	0.7965			

No marked High survival rate

High survival rate and significant difference (+)
Low survival rate but significant difference (+)

% Common in all cancer

	DR			DQ			DP	
%	APR_25 = RR	0.8571						
%	ARP_17 = AA	0.8571			-			
%	ARP_16 = VV	0.8571			 			
%	APR9 = WW	0.7109	%	AQP3 = PS	0.6237			
%	APR16 = YY	0.6563	%@	AQP9 = LY	0.6501	-		
*	ARP37 = LY	0.7202	%	AQP13 = AA	0.6568			
@	ARP57 = AV	1	%@	AQP37 = DY	0.628			
*	APR60 = YY	0.5806	%	AQP45 = EG	0.6029			
*	APR67 = FI	0.6366	%	AQP56 = PP	0.5597	%	APP57 = DE	0.6016
%	APR70 = DD	0.6583	%@	AQP66 = DE	0.6298			
%	APR74 = LL	0.7857	%@	AQP67 = IV	0.6298	%	APP84 = DG	0.5565
%	APR86 = GV	0.5752	%	AQP126 = HQ	0.6046	%	APP85 = EG	0.5565
%	APR120 = NN	0.8	%	AQP130 = RR	0.5593	%	APP87 = MV	0.5565
%	APR140 = TT	0.6635						
%	APR149 = HH	0.6717	%	A00407 IIII	0.000			
	70 10173 - 1111	0.0717		AQP167 = HH	0.6568			
			%	AQP185 = TT	0.6213			
			%	AQP197 = NS	0.6237			

No marked
High survival rate
High survival rate and significant difference (+)
Low survival rate but significant difference (+)
Common in all cancer

	DR		T	DQ	<u> </u>	T	DP	Т
%	ARP_25 = RR	0.7143	%	AQP_21 = GG	0.6208	 	DF	
%@	ARP_17 = AA	0.7143		AQP_6 = TT	0.6208	ļ		
<u> </u>	-	317110	%@	AQP_5 = PP	0.6208		<u> </u>	
%	ARR_1 = AA	0.5833	%	AQP_4 = VV				
%	ARP4 = QR	0.6692	/0	AQP_4 = VV	0.6208			
@	ARP9 = KW	0.8667	*	4000-104	100015			
%@	ARP11 = DP			AQP9 = YY	0.6315			
*		0.8462	%	AQP13 = GG	0.6271			
*	ARP13 = FS	0.7826	%	AQP14 = LM	0.6486			
	ARP26 = FL	0.5386	%	AQP23 = RR	0.5781			
*	ARP31 = FF	0.5618	%@	AQP30 = HY	0.6919	%	APP36 = AV	0.7225
*	ARP31 = FI	0.5981	%@	AQP57 = AA	1			
@	ARP33 = HH	0.8125	@	AQP66 = EE	0.6043			
@	ARP37 = NS	0.7281	@	AQP67 = VV	0.6043			
%	ARP38 = VV	0.5842	%	AQP71 = AT	0.6808	%	APP76 = IM	0.667
@	ARP40 = FF	0.5769	%	AQP74 = ES	0.5884			0.007
@	ARP57 = AAV	1	%	AQP77 = RT	0.6548			
%	ARP60 = HS	0.8	%	AQP84 = QQ	0.6117			
*	ARP67 = FL	0.6649	@	AQP86 = EG	0.786			
@	ARP71 = ER	0.7432	@	AQP87 = LY	0.7151			
@	ARP74 = AE	0.6849	%	AQP116 = IV	0.6486	····		
%	ARP78 = VY	0.6635				 -		
%	ARP85 = VV	0.581	%@	AQP130 = QR	0.7567			
%	ARP86 = GG	0.5924			2.7007			
%	ARP98 = EK	0.6531					· · · · · · · · · · · · · · · · · · ·	
%	ARP104 = AS	0.6531	%	AQP167 = RR	0.6271			
			%	AQP224 = QR	0.6486			
%	ARP120 = SS	0.597		7.4.227	0.0400			
%	ARP133 = RR	0.592						
%	APR142 = VV	0.592			survival ra			}
%	APR149 = HH	0.619		@ High s	Survival rat	te and s	significant differen gnificant differenc	ice (+)
@	ARP166 = RR	0.5791		% Comm	non in all c	ancer	giiiicani differenc	se (+)
%@	ARP231 = QQ	0.5848						

Fig. 44

		Chemomerapy	Immunotherapy
	_		
	Date: Use Home		(-), hetero>homo
- -			(-), heterozhomo
5			
			(-) homo>hetero
			1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	Heterosnomo		
†			
	TOTHO! HEIGHDS (*)		
2		3	
	Hetero (-)>homo		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	DP11 G DP11 L	د ق	د ق

ımmunotnerapy									+			E homo,((-))			(-)>hetero	(-)>hetero			Vhomo>(f.)) hetero			V homo>((-)) hetem		Hetero (-)>Lhomo			Helero,(-)>Enomo
Cilemonielapy												(-),homo>hetero			Same	Same			(-),homo>hetero				(-),homo>hetero		Hetero,((-))>homo Hetero (-)>Lhomo		Lotory (// // protor	netelo,((-)/>nomo Herero (-)>Enomo
												homo,hetero>(-)			(-)>hetero	(-)>hetero			Same				Same		Same		Homoshetero (1)	(-)(-)(-)(-)(-)
											30 G					(DK166) K		30 L			• •	·				'		- :- -
											DR30				9	á		DR30										
•											I				λ			Q a	4									
											DR28				DR40			DR25										
											>				∢			ш ~										
											DR26				DR38			DR14										
															>	7	· -	>		α	Щ					ပ		
											DR11				DR31	DR12	DR12	DR13		DR13	DR31	DR31				DR30		
× 1	2 1	٦	4	-	4	>	တ	4	a	œ:		п c	3;		π _	S		ပ	7	۳	L	_ 	: u	o	ı LL		Ш	P
	2 2	DR 24	DR_17	DR 17	DR_16	DR 16	DR_1	DR 1	DR4	DR4	DK9	DR40		טואט	UKIO	DR11		DR11	DR11	DR11	DR13	DR13						DR28 [
	되				-	-				<u></u>			5 6			-								-	*		****	
R. 6		Jcer	Cer	Cer	Cer	Cer	Ser	8	8	8:8	3 i 8) ! c) ! C	J · ·				· :	J					, ,				
R. 6		Stomach Cancer	ch Cance	Stomach Cancer	Stomach Cancer	Stomach Cancer	Stomach Cancer	Stomach Cancer		Stomach Cancer	Stomach Cancer	Stomach Cancer	Stomach Cancer%		Stomach Cancer	Stomach Cancer%	Stomach Cancer	Stomach Cancer	Stomach Cancer	Stomach Cancer	Stomach Cancer	Cance						

DR38 A DR40 F DR40 Y							۲:	DR77			
: > I		z L o	D T > < ω	⋖ Ш	I	ם ב		G DR7	>>	- <	>0
DR32	DR33	DR33 DR37 DR37	DR47 DR47 DR57 DR57	DR58 DR58	DR67	DR67 DR70	DR73	DR73	DR78	DR85	DR85

DR 25 K DR 2	DR 25 K DR 2	Stomach Cancer	DR133 L		DR14 N	5				'. - ·	NO.	Спетотпетару	ımmunotnerapy
DR 24 F DR 24 P DR 2	DR 25 K DR 2	Stomach Cancer											
DR 25 K DR 2	DR 149 Q Circle R	ch Cancer								·			
DR 166 G Compared	DR 166 Q Circletion Same Circletion	ch Cancer		æ									
DR 166 R Control Con	DR 166 R C(2) Prietin C(2) Prietin C(3) Pri	ch Cancer		C				7		-	(-)>hetero	Same	(-1>hetem
DR 180 L Control Con	DR 180 L Corr DR 180 V Corr DR 180 V Corr DR 180 S Corr DR 231 R Corr DR 233 T Corr DR 25 K Corr DR 25 K Corr DR 25 K Corr DR 25 K Corr DR 26 V Corr DR 26 V Corr DR 26 V Corr	cancer cancer		~							(-)>hetero	Same	(-1>hetero
DR 25 K DR 25 K DR 25 K DR 26 K DR 27 K DR 2	DR180 V Corr DR180 R Corr DR180 R Corr DR231 P Corr DR231 R Corr DR233 R Corr DR233 T Corr DR25 K Corr DR25 K Corr DR25 K Corr DR25 K Corr DR26 K Corr DR26 K Corr Co	th Cancer								·	-		
DR 25 K DR 25 K DR 25 K DR 27 K DR 2	DR 189 R Second DR 189 S Second DR 189 S Second DR 189 S Second DR 21 Q Second DR 21 Q Second DR 24 F Second DR 17 T DR 16 K DR 16 K DR 16 K Second DR 16 K	th Cancer		_									
DR 23	DR 189 S DR 189 S DR 189 S DR 231 P DR 232 R DR 233 T DR 24 F DR 24 F DR 24 F DR 25 K DR 26 K DR 26 K DR 27 K DR 28 K DR 27 K DR 28 K	th Cancer	ı	~									
DR231 P DR231 C DR233 R DR253 T DR255 K DR256 K DR256 K DR256 K DR266 V DR26 K DR266 V DR26 K DR266 V DR26 K DR266 V DR26 K DR30 G DR30 W DR266 V DR26 K DR30 G DR30 W DR266 V DR26 K DR30 G DR30 W DR26 W D	DR231 P DR231 R DR233 R DR24 K DR25 K DR24 L DR24 L DR24 L DR26 V DR28 H DR30 G DR4 R DR	ch Cancer											
DR231 Q Corr DR233 R Corr DR233 R Corr DR233 R Corr DR25 R Corr	DR231 Q DR233 R	th Cancer								-1			
DR_23 R R R R R R R R R R	DR 23	th Cancer		~						. .			
COEF DR233 T STATE OF 25 K DR 25 K DR 24 L DR 17 T DR 16 A DR 16 A DR 16 A DR 1 B DR 1 A DR 1 B DR 1 A DR 1 A DR 1 B DR 1 A DR 1 B DR 1 A DR 1 B DR	DR_25 K DR_25 K DR_24 L DR_17 A DR_16 V DR_16 V DR_16 V DR_1 S DR_2 V DR_3 G DR_3 C DR_3 V	th Cancer		ر ا						<u></u>			
DR_25 K DR_24 F DR_24 L DR_17 A DR_17 A DR_16 V DR_16 V DR_1 S DR_1 S DR_1 A DR_1 S DR_1 A DR_1 C DR_2 C DR_3 C DR_3 C DR_3 C DR_3 C DR_3 W DR	DR_25 K DR_24 F DR_24 L DR_17 A DR_17 A DR_16 V DR_16 V DR_1 S DR_1 S DR_1 S DR_1 S DR_1 S DR_1 S DR_2 V DR_1 S DR_2 V DR_3 G DR_3 V DR	th Cancer	-										
DR_25 K DR_24 F DR_24 L DR_27 F DR_17 A DR_17 A DR_16 V DR_18 V DR_18 V DR_18 Q DR_18 Q DR_28 R DR_28 H DR_28 V DR_28 W DR_28 H DR_28 V DR_28 W DR_28	DR_25 K DR_24 F DR_24 L DR_24 L DR_17 A DR_17 A DR_16 V DR_1 6 V DR_1 8 DR_1 A DR_1 A DR_2		1							-'			
DR 25 K DR 24 L DR 24 L DR 24 L DR 24 L DR 17 A DR 16 V DR 16 V DR 1 S DR 1 S DR 1 A DR 1 A DR 1 A DR 2 C DR 1 A DR 2 C DR 2 C DR 3 C DR 1 A DR 4 C DR 4 C DR 4 C DR 6 V DR 6 V DR 6 V DR 7 A DR 8 C DR 9 K DR 9 W Homoshetero (1)	DR_25 K DR_24 F DR_24 L DR_17 A DR_17 A DR_16 V DR_16 V DR_1 S DR_4 Q DR_4 Q DR_4 A DR_4 Q DR_4 A DR_4 A DR_4 A DR_4 A DR_4 B DR_4 A DR_6 W DR_7 A DR_7 A DR_8 W DR_8 W DR_9 W DR									<u></u>			
DR 25 K DR 24 F DR 24 L DR 17 A DR 16 A DR 16 V DR 1 S DR 1 A DR 2 A DR 3 A DR 4 A DR 4 A DR 4 A DR 5 A DR	DR 25 K DR 24 F DR 24 L DR 17 T DR 16 V DR 16									!			
DR_25 K DR_24 F DR_24 L DR_17 A DR_16 A DR_16 V DR_1 S DR_1 S DR_1 A DR_28 K DR_1 DR_28 H DR_30 G DR_30 C	DR 25 K DR 24 F DR 24 F DR 24 L DR 17 T DR 16 A DR 16 V DR 16 V DR 1 A DR 2 A DR 1 A DR 1 A DR 2 A DR 1 A DR 2 A DR 3 A DR 3 A DR 4 C DR 4 C DR 4 C DR 4 C DR 6 V DR 6 V DR 7 A DR 1 A DR 2 A DR 1 A		•							!			
br 25 K	b DR 25 K												
DR 25 R DR 24 F DR 24 L DR 17 A DR 16 A DR 16 V DR 16	DR_25 K DR_24 F DR_24 F DR_17 A DR_17 A DR_16 A DR_1 S DR_1 S DR_1 A DR_2 R DR_4 Q DR_4 R DR_26 Y DR_28 H DR_30 G DR_10 Q DR_10 Q DR_10 Q			ſ									
DR_25 R DR_24 F DR_24 L DR_24 L DR_17 A DR_16 A DR_16 V DR_1 S DR_1 A DR_26 Y DR_28 H DR_30 G DR_30 R	DR_24 F DR_24 L DR_24 L DR_17 A DR_16 A DR_16 V DR_1 S DR_1 A DR_1 A DR_2 B DR_3 G DR_3	ancers	ر ارک							'			
DR_24 F DR_24 L DR_17 A DR_17 T DR_16 V DR_1 S DR_1 S DR_1 A DR_1 A DR_2 C DR_1 A DR_2 C DR_3 C DR_4 C DR_5 F DR_5 F DR_5 C DR_5	DR_24 F DR_24 L DR_17 A DR_17 T DR_16 A DR_1 S DR_1 S DR_4 A DR_9 K DR11 D DR26 Y DR28 H DR30 G DR10 Q DR10 Q	ancers	52							'		1	
DR 24 L L A DR 17 A DR 16 A DR 16 V DR 1 A DR 16 C	DR_17 A	ancers								· - '			
DR_17 A DR_16 A DR_16 V DR_1 A DR_28 H DR_30 G DR_28 H DR_30 G DR_29 W	DR_17 A DR_16 A DR_16 V DR_16 V DR_1 S DR_1 A DR_4 Q DR_4 R DR_9 K DR11 D DR26 Y DR28 H DR30 G DR9 W herero (-)>homo>hetero.(-) DR10 Q	ancers	47										
DR 17 T	DR_16_ A A DR_16_ V DR_16_ V DR_16_ V DR_16_ V DR_16_ V DR_17_ C DR_16_ C DR_16_ C DR_16_ C DR_16_ C DR_17_ C DR_16_ C DR_18_ C DR_19_ C DR_19_ C DR_100_ C DR_10_ C DR_100_ C	ancers	14							' -			
DR_16_ A A DR_1 S A DR_4 Q A DR_4 R A DR_4 R A DR_9 K DR_1 DR_26 Y DR_28 H DR_30 G DR_9 W Nomo>hetero (1)>homo>hetero (2)	DR_16 A A DR_1 S DR_1 S DR_1 A DR_4 Q DR_4 R DR_9 K DR_9 W Nome the control of the c	ancers	DR 17 T							٠			
DR_16 V V DR_1 S DR_1 A DR_4 Q DR_4 R DR_9 K DR_26 Y DR_28 H DR_30 G DR_9 W Nomo>hetero (.)>homo>hetero (.)	DR_16 V V DR_1 S DR_1 A DR_4 Q DR_4 R DR_9 K DR11 D DR26 Y DR28 H DR30 G DR9 W homo>hetero,(-) DR10 Q homo>hetero,(-)	ancers	9							<u></u>			
DR_1 S DR_4 Q DR_4 R DR_9 K DR_26 Y DR_28 H DR_30 G DR_9 W homo>hetero (.)>homo>hetero (.)	DR 1 S DR 1 A DR 4 Q DR 9 K DR 11 D DR 28 H DR 30 G DR 9 W homo>hetero,(-) homo>hetero,(-)	ancers	9	-						<u></u>			
DR 1 A DR4 Q DR4 R DR9 K DR11 D DR26 Y DR30 G Herero (1)-homo herero (2)	DR4 Q DR4 Q DR4 R DR9 K DR11 D DR26 Y DR30 G DR9 W N homo>hetero,(·) DR10 Q nomo>hetero,(·)	incers	-	_						٠			
DR4 Q DR4 R DR9 K DR11 D DR26 Y DR30 G herero (1)>homo>herero (2)	DR4 Q DR4 R DR9 K DR11 D DR28 H DR30 G DR9 W homo>hetero,(-) DR10 Q	incers	_							 -	-		
DR4 R DR9 K DR10 D DR26 Y DR28 H DR30 G Inerent (1)>homo>hetero (2)	DR4 R DR9 K DR11 D DR26 Y DR28 H DR30 G DR9 W homo>hetero,(-) DR10 Q	ıncers								_'			
DR9 K DR11 D DR26 Y DR28 H DR30 G DR9 W homo>hetero (-)>homo>hetero (-)	DR9 K DR11 D DR26 Y DR28 H DR30 G DR9 W homo>hetero,(-) DR10 Q	ncers								-'			
DR9 W homo>hetero (-)>homo>hetero (-)	DR10 Q homo>hetero.(-)>homo>hetero.(-)	ncers				DR26	1	DR28	DR30	ပ			
	DR10 Q	ncers		_								homo>hetero (-)	hetero (homo)>

Fig. 48

Immunotherapy			homo>hetero,(-)	nerero (-)>nomo homo,hetero>(-)	homo (-)>hetero			(-) (hetero)>homo	(-),(hetero)>homo	()/010404	hetero,((-))>homo		hetero>(-)	(-) hetero)>homo	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	netero>(-) Same		homo>hetero,(-)	
Chemotherapy			Same	(-),(hetero)>homo	(-) heterol>homo	8		(-),hetero)>homo	(-), hetero/>homo	() Shotonos homos	homo>hetero,(-)		(-)>hetera>homo			hetero ((-))>homo		homo,(-)>hetero	
No.			hetero.(-)homo	Same	Same			homo,(-)>hetero	homo,(-)>hetero	o He o	(-),hetero)>homo		Same	Same		(-),hetero)>homo		hetero,(-)>homo	
																_ 3000			· • · • · • · •
		DR30																	
		αĸ				< >													
		DR25 DR25				DR85 DR85													
		田木					<u>ь</u> >]									 ⊢ Z]	
		DR14 DR14														- 1			
						DR38	OR40)R77)R77		
	ㅈ ⊢		œ	c	9	L DR38	A DR40									ľ	R DR77 N DR77		
	⊼ ⊢	>				٦	∢										ĽΖ		
>	DR12 K DR12 T	DR13 Y	P DR13 R S	0630	2000	H DR37 L DR38	DR38 A		≻ I	ZIII	S	1 > "	\				DR74 R DR74 N		
	S DR12 K DR12 T	G DR13 Y	P DR13 S	H DB30	0	H DR37 L	V DR38 A	Ι;		33 N 37 F			47 Y 57 A			A	A DR74 R G DR74 N	74 L	× 80 €
DR10 Y	S DR12 K DR12 T	G DR13 Y	DR13	H DB30	0	DR37 L	DR38 A	Ι;	DR33 H	DR33 N DR37 F	DR37 S				DR58 E DR60 H	A	A DR74 R G DR74 N	DR74 L DR78 V	DR78 Y

Immunotherapy		homo,hetero>(-)	homo,hetero>(-)	hetero,((-))>homo	(-), hetero)>homo	(-) hetero)>homo			Same	Same											(-) hetero)>homo
Chemotherapy		hetera homo>(-)	hetero, hoo>(-)	Same	Same	Same			Same	Same											hetero),(-)>homo
No.		Same	Same	(-) hetero)>homo	hetero,(homo)>(-)	netero,(homo)>(-)			(-) netero)>homo	(-) hetero)>homo											сате
																					i
			7	DR10 4	CB10			DR14 V	DR14 M			1		1		ī					
- > 15	9 6	> (5	G	ш	K DR10	Z	ဟ Q	_	œ	a	Н 6	O 9	- A-	7 0	_ > 0	X 6	- o			2	
DR85 V	DR86 G	DR86 V		ш	K DR10		DR120 S	DR133 L DR14 V		a	DR149 H	DR166 Q	DR166 R	DR180 L	DR180 V	DR189 R	DR189 S	DR231 P	DR231 Q	DR233 R	DR233 T

(Ξ	כ
L	ĺ	Ď
		٠.
i	C	Ď
	=	=
L	1	_

Immunotherapy												hetero>(-)>homo	Hetero>(-)>homo (Differe	from 30Y)										hetero,(-)>homo					
Chemotherapy					3							<u> </u>			hetero>(-)'homo	hetero>(-),homo									hetero>(-),homo	i			
0			-										••							<u>.].</u> .	<u>.</u>							 	
				L DQ55																									
				2 2 2	22																								
			L																										
			D047	DQ47																									
			>		-																								
			- 1		1																								
			DQ46	DQ46																									
			DQ46	DQ46			_		_																				
			l DQ46	DQ46		(Although	there are not	ss, it is	almost the																				
			_	DQ46	037		there are not	ss, it is	almost the					-]			
			S DQ37 I DQ46	DQ46	DQ37		there are not	ss, it is	almost the					-											>				
			S DQ37 I	DQ46	DQ37		there are not	L samples, it is	almost the same					-										1 29					
- 2	≥	1 00	DQ30 S DQ37 I	Τ DQ46	DQ37		there are not	ss, it is	almost the same		> :	I			^	ш	ပြ		2	1.0	-1-		l>	D DQ67 I	DQ67				
			S DQ30 S DQ37 I	F-	DQ37		there are not	P DQ9 L samples, it is		S														۵	E DQ67				
			DQ30 S DQ37 I		D037		there are not	DQ9 L samples, it is		S	DQ30 ×									7 CC20					E DQ67			DQ14 L	
DQ14	D023	DQ23	DQ28 S DQ30 S DQ37 I	DQ28 T	DQ37			DQ3 P DQ9 L samples, it is		DQ3 S	DQ30	0000		DQ38	DQ38	DQ45	DQ45	DQ53	2000	0055	D056	DQ56	DQ57	DQ66 D	DQ66 E DQ67			DQ14	7
DQ14		DQ23	DQ28 S DQ30 S DQ37 I	F-	DQ37			P DQ9 L samples, it is		S	DQ30	0000		DQ38	DQ38		DQ45	DQ53	2000	0055	D056	DQ56	DQ57	DQ66 D	DQ66 E DQ67				2

Fig. 51

_		_	_ •													_	_			
Immunotherapy							hetero (-)>homo													
: Chemotherapy	73							hetero,homo>(-)											hetero (-)>homo	hetero (-)>homo
 No.					(-) hetero>homo	(-) hetero>homo		hetero,homo>(-)	hetero,hoo>(-)	hetero homo>(-)										
			DQ47 F : DQ52 L : DQ55 L	DQ47 Y DQ52 P																
			S : DQ37 : DQ46 E	DQ46 V	DQ37 D														<u> </u>	
		œ	S D030 S	T :	P DQ9 L	S		<u>-</u> [<u></u>	ш	Ø	Γ.	a	۵	~		a .) DQ67 I	DQ67 V
	DQ23	DQ23		DQ28		DQ3	000	600	0038	0038	DQ45	DQ45 (DQ53	DQ53 (DQ55	DQ55 F	DQ56 1	DQ56 F	DQ66	0066
	Other cancers	_	;		:	- !	;	Ļ	Other cancers	ᆜ	-		٠.,	,—,	_	_	Other cancers		ļ.,	Other cancers

25	
g S	
Ĕ	

Prognosis	Total (hom	Other cano					A, Shomohete		***************************************		Phetero>hc		Fhatero>(-) Rhetero>h(-) Shetero,(-)	ZHOHIO			Fhetero>hr			Fhetero>hc hetero>(-)
Prognosis	Total (+) vs	Other					A(+)>(_), S(-)>(+)						F(+)>(-)							(+)z(+)
Prognesis	Stomach		RR71.4	6 09 11	AA67.8	VV71.4	SS100	RR68.1	KW75.8	EY75	LL100	TT70.7	SY100, GR75.4	EKBO	HQ830		LY80.3	DE69 4	CC1000	FV76.2
Prognosis	Total (homo)	Stomach						***************************************			Vhetero>(-)				Chetero>	21121	Lhetero> homo	2		
Prognosis	Total (+) vs (-)	Stomach		F(-)>(+)	, , , , , , , , , , , , , , , , , , ,													<u> </u>		
Prognosis	Total		RR78.8	FI66.7	AA76.6	W78.8	SS83.36	QR68.3	KW74.2	EY83.3	GV100, LL1000	KK66.5	HY100, FR71.6	FF66 2	HQ71.50		LY70.2	DE69 2	GC1000	FV77.8
	mo)		ero, hetero		Ahomo>hetero, T(-	A(+)>hetero, Vhomo>hetero					tero									
Prognosis	Total (homo)	Total	K(-)>hetero. Rhomo>hetero		Ahom	A(+)>hetero. Vhomo>hete					V(-)>hetero									
···	Total (+) Total (hc Vs (-)		K(-)>het		Ahom (>)hete	A(+)>h					V(-)>he									
···		Total		T=J		A=V A(+)>H	A=S	Q=R	9K=11D=26Y=28H=30G	10E=31V=38A=40Y= (166Q)=(166R)	~		13F=31F=31I	E=K		Q=R		28H=30G	30H=37L=38L=85A=85V	31V=38A=40F=40Y, 31 (F=I)
Prognosis	Equivalence Total (+)	ersity Total	K=R		A=T				EKW 9K=11D=26Y=28H=30G		~		FGHRSY 13F=31F=31	EK E=K		QR Q=R		 -	LRY	
Prognosis	Diversity Equivalence Total (+)	Diversity	KR K=R	1=4	AT A=T	A=V	A=S	QR	EKW	ΕΦΥ	DGLPSV 11G=13Y=14E=14=K25 Q=25R=30L, 11S=12K=12T, 11P=13R	ΚŢ	FGHRSY	EK	НФУ		FLY	DEH	├ -	FIV

				Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Drognosic	Drognocie	Drognosti.
		Diversity	Equivalence	Total (+)	Total (homo)	Totol	T-1-1-1-1	200 B	pionika:	109110313	SISOLIDOLL
				(-) (-)	י סנפו (יוסוווס)	0.0	l otal (+) vs (-)	l otal (nomo)	Stomach	lotal (+) vs	Total (homc
	DR.	Diversity		T.0401	7-4-1					[-]	
	: i		· · · · · ·	- 01al	l otal		Stomach	Stomach		Other	Other canci
9	arn32	<u> </u>			***************************************					cancers	
5 5	704					HY66.9			XY68		
7	arpss	ZH	Z=L			NN66 7			UU71 /	***************************************	
99	arp37	FLNSY	F=S		***************************************				11/11/		
	-)			000			FS73.4		F(-),
29	arp38	ALV				000					netero>non
69	arn40	ΕV	F=V			LLOUC			AV/8.8		
76	25017	<u> </u>				FY73.1			FY71.6		
2	4104/	L 1	Γ=Υ			FY67.4			YY68 Q	***************************************	
 92	arp57	ADSV			Shefero (-1>homo	AV73 70			AD70 F		1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1
					ana (Name)			0,777		r-)'olajalio
87	arp58	AE	A=E			AE67			07/77		пото
83	arp60	HAY				AE0/			AE/1.1		***************************************
96	arp67	FIL				13/3./			HY68.4		
66	arp70	DQR				7100.3			F1/2.2		
100	arb71	AFKR				4.0000			DD/2./		
					K(-J>hetero	AR63.5,	K(-)×(+)	K(-)>hetero	EK750		A Ehetero>
						ER67.2,					ното
	arn73	0	4. 4. 4. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6.			AE/2.6					
	2		/3A=/3G=/4K=/4N= /7N=77T			AA66.3			AA68.1		
103	arn74	1	0-1								
3	11/2	- 1	N-4			LR80			AQ100 O		
3	arp//	Z	L=Z			TT66.4		***************************************	TT68.2		***************************************
107	arp78		\= ∧		***************************************	VY67 1			1.00.1 1.00.0		
							•				

Produceis	Total (hom	2	Ourier capc			07.7																***************************************		R Thetarn	Vhomo V		
Prognosis	Total (+) vs	(-) Other	cancers										R(+1>(-1		1751+1/1												
Prognosis	 			VV68.1	VV69.4	EE100		EK72.1	AS72.1	NN72.9			LL69.7	TT74.1	MM69 7	HH70.8		QR68.6.	RR68.6	LL70.1	1769	SS100	00679	RR78.2		DR30CLC	C(4)
Prognosis	Total (homo)	Stomach																	9					R, Thomosh	etero (-)		
Prognosis	Total (+) vs (-)	Stomach																						T(-)>(+)			
Prognosis	Total			AA80	GG68.5	EE100		EK68.5	AS70.5	0.77NN			KR67.5	TT71.5	VV67.5	HH68.1		RR67		LL75.1	TT67.3	SS100	QQ66.7			UK11GLGV	LE(0)
Prognosis	l otal (homo)	Total			*************************					N(= IShatem Shomosk	/ Hetero, Shoring/II																
Prognosis	Vs (-)	Total																									
Equivalence			A=V	G-V			98E=98K=104A=142V	A=S	N=S	:		133L=133R=142M=142V	A 71	M=V	CIL	3	O=R		Γ=V		R=S	P=O	R=T	-			
Diversity	, ,	Diversity	AV	QV GV	EHOY		ĘĶ	AS	NS			LR	AT	MS	HOY	FV	OR		-		 		-		All	survived	
	Q.	<u> </u>		115 arp86	ļ		127 arp98		149 arp120		 }-	+		171 arp142	178 arp149	arp164	195 arp166		209 arp180	210 arp181			Ļ				•

Treatment		Stomach can								Immunothera	KW 84 6								7			Immunothera LY66.7		mmunothera (68.6)			
Treatment Effect	Total (homo)	rotal (iloino)	Stomach							Immunotherapy E (-),	(nomb)>herero Immunotherapy E(-)	Znetero	Immunotherapy	Vhoma,((-)) >hetero			Immunotherapy Hhomo ((-))>hetero					Chemotherapy Lhetero ((+))>homo,	Lhetero,(-)>homo	Enetero (-) >homo			mmunomerapy V()>hetero
Treatment	Effect Total (+) vs (-)	Ctompoh	otoliacii								Immunotherap	(11/2/11)													Immunotherap y R(-)>(+)		y V(-)>(+)
Treatment Effect	All cases					Immunotherapy AA 71 4			mminotheraniiMat	(86.7)			no adjuvant therapy	DS(83.4)DV(79.6), Immunotherapy DP (84.6)	(0.50)		no adjuvani therapy GH(89.9), Imminotheram	ES(810)				no adjuvant therapy FL(87), Immunotherapy FL(61.4)				Immunotherapy FF	
Treatment Effect	Total (homo)	Total									Immunotherapy E(-)		Immunotherapy	vituillu,((*))/Anetero										Ehetero (+)>homo)>hetero	Immunotherapy V (-	Shetero
Treatment Effect	Total (+) vs (-)	Total									Immunotherapy E(-)>(+)						Immunotherapy Shetero> (-),homo					Chemotherapy 26L(+)>(-)		ng adiliyant	therapy H(+)>(-) Immunotherapy	Immunotherapy	(+)<(-)
Prognosis	Other cancers		DD100	1400	A A 4 00	W/100	449000	00693	KW71.2		EY100	1 1000	99		0 10010	NN04.2	FR74.20		EE63.5	QY100		LL100	EE83.3	CC100		FV80	
	Equivalence		K=R	F=	A=T	A=V	A=S	Q=R	9K=11D=26Y=28	506-11	10E=31V=38A=4 0Y=(166Q)=(166 R)	11G=13Y=14E=1	4=K25Q=25R=3	0L, 11S=12K=12T, 11B=13B	751-13K	401-401	137=137=371	7-2		O=R			28H=30G	30H=37L=38L=8	5A=85V	31V=38A=40F=4	1 7
-	Diversit	Diversit v	좄	F	┼	 	AS	aR R	EKW		EQY	DGLPS	>		KT	ECUDO		πX	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	200	> 0		DEH	CGHLR		FIV	
		R	arp 25	arp 24	arp 17	arp16	arp1	arp4	arp9		arp10	arp11			arp12	arn13)	arp14	arn16	arp25	arn26	0	arp28	arp30		arp31	

	Treatment Effect	Stomach cancer		- Immunotherapy HH(87.5)	immunotherapy NS(69.1)					Chemotherapy FF(74.5) no adjuvant therapy SV(7) immunotherapy AD(83.3)				Chemotherapy II(74.8)	no adjuvant therany DO	(86.5) (No adjuvant therapy	AA(77 8) Chemotherapy AA (58)	no adjuvant therapy EL(90 Chemotherapy AL (66.1), Imminotherany, A E 67.51	Chemotherapy TT(58)	
	Treatment Effect	Total (homo)	Stomach	Immunotherapy Phomo>((-	N(-)>(homo), hetero		Immunotherapy A(-)>hetero	Immundtherapy Y (-)>hetero.						Chemotherapy inomo-hetero(-). Chemotherapy L(-), homo-hetero	no adjuvant therapy	Dhetero-homo (.)	Chemotherapy Ahomoshatero	Chemotherapy G(-)-hetero Immunotherapy Ahetero((-))nomo Chemotherapy(-)-hetero	Chemotherapy N(-)>hetero, Chemotherapy
	Ireatment Effect	Total (+) vs (-)	Stomach	Immunotherapy N(-)>(+)			Immunotherapy A(-)>(+)									no adjuvani therapy K(-)>(+)	Chemotherapy G(+)>(+)	Chemotherapy R(-)>(+)	Chemotherapy	N(+)>(+)
1.21	Treatment Ellect	All cases			Chemotherapy LY(70.9), immundherapy NS(72.5)			Immunotherapy FF(57.5)		no adjuvant therapy SV(92.2), Chemotherapy DD(60.3), immunotherapy	AD(76.2)		Chemotherapy YY (56.8)	no adjuvant therapy IL(82.8), Chemotherapy FI(63.4), Immunotherapy FL(68)		no adjuvani linerapy RR(81.8), immunotherapy	ER(73.7)	Immunotherapy AE(67.9)		
Treatment Effect	Total (homo)	Total	200		Chemotherapy F(-)>hetero.homo.	Immunotherapy Nhetero (homo)>(-)	Immunotherapy A(-)>hetero	Immunotherapy Fhomo>hetero Immunotherapy Y(-	Phetero	no adjuvant therapy Shetero ((-))>homo				Immunotherapy I(-)>homo, hetero, no adjuvant therapy Lhetero>(-),homo, Chemotherapy L(-	Janetero, nomo	no adjuvant therapy Ahetero. ((-))>homo,	Ehelero ((-))>homo	Immunotherapy Ahetero,((-))>homo, Immunotherapy	Energinomo>(-)	
Treatment Effect	1	Total			Chemotherapy F(.)>(+), no adjuvant therapy L	N(+)>(-)	Inititudionerapy A(s)>(+), no adjuvant therapy L(+)>(-)	Immunotherapy Y(-)>(+)		Chemotherapy A(-)>(+)		Chemotherani	Circulation (5) 2 (4)	Chemulatre apy (-,)>(+)	Chemotherapy R(-)>(+)	no adjuvant therapy K(÷)>(+)		Chemotherapy E(+)>(+), Immunotherapy E(+)>(-)		
Prognosis	Other cancers		HY64.8	HN64.5	FL83.30	11100		FY75	FY67.3	AV88 90	AA63.5	HS88 9	FF72 4		RR69.4	KR78.60	AG65.6,	ER1000	NT83.3	
	Equivalence		/= Η	Z 	R=S			-	F=Y		A=E						73A=73G=74 R=74N=77N= 771	R=N	L=N	
	Diversity	Diversity	ΣÌ	Ē	FLNSY	ALV	,	L	FΥ	ADSV	AE	НАУ	FIL		DOR	AEKR	AG	AELQR	F	
		צ	arp32	2 8	arp37	arp38	9	<u> </u>	arp47	arp57	arp58	arp60	arp67		arp70	arp71	arp73	 	arp77	

Fig. 57

	!		Prognosis	Treatment Effect	Treatment Effect	Treatment	Treatment Effect	Treatment Effect	Treatment Effect
	Diversity	Equivalence	Other	Total (+) vs (-)	Total (homo)	All cases	Total (+) vs (-)	Total (homo)	Stomach cancer
DR	Diversity			Total	Total				
arp85	۸۷	A=V	AA100	no adjuvant			Stomacn	Stomacn	
90				therapy A(+)>(-)					
alboo	20	V=0	GG64						
arpgo	EHQ Y		EE1000		no adjuvant therapy Q(-),hetero>homo	no adjuvant Iherapy			
arp98	Ę	98E=98K=104A=104S	ED68.2			H1(0 0)			
arp104	AS	A=S	AS68.2						
arp120		N=S	NN85.7		Immunotherapy Nhomo<((-)), hetero, immunotherapy S(- is(homo) hetern				
arp133	LR	133L=133R=142M=142 V	LR67.6			no adjuvant therapy DD773.0			
arp140	AT		TT67.4			תעונסא			
arp142	AN M	M=V	MV67.6			no adjuvant therapy			
arp149	НОУ	H=Q	0.064.7			(SA)AA			
arp164									
arp166	a R	Q=R	RR64.2	Immunotherapy Q(-)>(+)	Immunotherapy Q(-)>hetero, Immunotherapy R(-)>hetero	Immunotherap y RR(57.5)	,	Immunotherapyl(-)>helero, Immunotherapy R(-	immunotherapy RR(55.2)
arp180	۲۸	Γ=V	LL83.3					/-IIIII (Callie)	
arp181	MT		MM68.1						
arp189	RS	R=S	SS100		***************************************			***************************************	
arp231	Q.	P=Q	QQ64.7	Immunotherapy P(-)hetero, Immunotherapy Qhetero>homo	Immunotherapy P(-)>hetero, Immunotherapy Chetero>homo	Immunotherap y QQ(57.5)		immunotherapy P(- 2-helero, immunotherapyOhete ro-	
arp233	RT	R=T	RT65.9					HOHIO	
	All survived	٧=٨	DR96EE(3)						

		Treatment Effect	Treatment Effect	Treatment Effect	DR	DR	DR	DR
Equivalence	ဥ	Total (+) vs (-)	Total (homo)	Other cancers	Cancer in Family	Metastases	Total t(ratio of	Smoking
Diversity		Other cancers	Other cancers				advanced cancer)	
Α - R								4
교								
A=T						FL80 LL22 90		
A=V								
A=S				1 1 1 2 2 2 2				
Q=R				to adjuvant merapy AA (100)				AS733, AA44.40
9K=1 =28H	9K=11D=26Y =28H=30G		no adjuvant therapy Whetero (-)	no adjuvani therapy KW(88.9)				
10E=	10E=31V=38A		OHIOH					
=40 V	=40Y=(166Q) =(166R)							
1	137-11							
	F=137=14 E=14=K25Q=		no adjuvant fibrany Phatero ()					
25R:	-30L		aletapy interesule) Shomo					
113	11S=12K=12T		2					

13F=	13F=31F=311		no adiivant	100 GT Hashings on				
			therapy Rhetero.(-	Chemotherapy FR(72), Immunotherapy FS(100)			FT22.6, FF0, GR0, O	
			Chemotherapy Shetero (-)>homo, Immunotherapy					
품			Shelero>(-) homo					
			***************************************			**		
Q=R							QQ100, YY6, 30	
			Chemotherapy F(-),			#		
28H=30G	30C		Chemotherapy haters (1) shome	Chemotherapy EE 100		#		
30H=	30H=37L=38L		20000					
=85A	=85V							
31V≕ =40Y	31V=38A=40F =40V_31((F=1)							
-						-		

Fig. 59

			Treatment Effect	Transment Defent					
	Diversity	Fallivalance	Total (+) ve ()	Treatment Ellect	reatment effect	DR	DR	DR.	DR.
		Lydivalence	O(d) (+) VS (-)	l otal (homo)	Other cancers	Cancer in Family	Metastases	Total t(ratio of	Smoking
								advanced	
DR	Diversity		Other cancers	Other cancers				calicel	
arp32	λH	λ=H	Chomphoren VIII	Out cancers					
		•	Immunotherapy Y(+)>(+) Chemotherapy H(+)>(+)	Chemotherapy Hit.), helero-homo, Immunotherapy hatero (-)-homo. Chemotherapy Yhetero, homo>(-), Immunotherapy	Chemotherapy HY(55.6), Immunotherapy HY(55.6)				
arp33	Z	N=H							
arb37	FLNSY	F=S						HN18.3 NN9.80	
) i	}		Chemotherapy F()(hetero)>homo. no adjuvant therapy Shetero,(no adjuvant therapy YY(81.3), Chemotherapy FS(100), Immunotherapy MS(80)				
arp38	ALV				(po)cu	7			
arp40	FΥ	F=Y				#			
arp47	FΥ	F=Y							
arjp57	ADSV		Chemotherapy A(-) >(+)	Chemotherapy A(-)> (hetero),homo, immunotherapy Shetero,(-	no adjuvani therapy SV(81.6). Chemotherapy VV(85.7). Immunotherapy				
arp58	AE	A=E		PAIGHIG	US(78.8)				
arp60	НАУ			Chemotherapy H(-	Chemotherapy SS(85.7),				
arp67	1111			// Indicated by Indilia	nnimumonierapy HTL(2) no adjuvant therapy FF85.7,				
arp70	DOR				(c/a)				
arp71	AEKR			no adjuvant therapy	no adjuvant therapy AR(74.9)				
arp73	AG	73A=73G=74 R=74N=77N=		anion d'Allanana					
		777							
arp74	AELQR	R=N	no adjuvant therapy L(-	no adjuvant therapy	no adjuvant therapy(AE81),				
arp77		L=Z			Citation apy Open 4				
arp78	≽	V=Y							***************************************

Fig. 60

.	ı		.		ı	1	ı	i	ı	ı	ı	i		ı	1	ı	ļ	1	ı	ļ		ı
au	Smoking																	#				
DR.	Total (ratio of advanced	cancer)				#				*												
DR			***************************************		*																	
DR	Cancer in Family			AV38.7, AA00						#	***************************************				***************************************	77	#					
Treatment Effect			***************************************		Chemotherapy VV(90)	no adjuvant therapy HY(100)	Immunotherapy EK(68.4)	Immunotherapy AS(81.9)		no adjuvant therapy RR(69.1)		no aduvant therapy VV(69.1)				no adjustant thousand 17/400)	110 aujuvani illerapy LV(100)			Immunotherapy RT(77.9)		
Treatment Effect	Total (homo)	Other connection	Callel Called S		Chemotherapy	no adjuvani therapy Q(-	Interior nono Immunotherapy Ehetero (-)-homo, Immunotherapy	Inmunotherapy Ahetero (- 12homo, Immunotherapy	Sueleto, nomos()	no adjuvant therapy Lhetero (.)>homo no adjuvant therapy Dhomo homo		no adjuvant therapy Mhetero.(-)>homo, no adjuvant therapy	VIOLED CALL							Immunotherapy Rhetero,(-	hetero.homo>(-)	
Treatment Effect	Total (+) vs (-)	Other cancers			Chemomerapy G(+)>(-)		Immunotherapy K(+)>(-)	Immunotherapy S(+)>(-)		no adjuvant therapy R(+)>(-)		no adjuvant therapy V(+)>(-)								Immunotherapy T(+)>(-)		
	Equivalence		A=V	7-0	2		98E=98K=104 A=104S	A=S	N=S	133L=133R=1 42M=142V		M=V	H=0		Q=R	L=V		R=S	P=0	R=T		
	Diversity	Diversity	AV	ج(5	ЕНОУ	Ä	AS	NS	ļ	AT		НОУ			۲۸		RS	Pa	RT	V V	Survived
		DR	arp85	arna6	3	arp96	arp98	arp104	arp120	arp133	arp140	arp142	arp149	apr164	arp166	arp180	arp181	arp189	arp231	arp233		

(Š	5	
	ζ	j)
Ĺ	ī	_	

Treatmen	Effect All cases		· ·							no adjuvan therapy	AD(79)				no adjuvan therapy EK (81,				
Treatment	Total (homo)	(camp)	Total												no adjuvant therapy Enetero-(-)),homo, no adjuvant therapy Khetero-(h	7 10 200 2			
Treatment	Total (+)	vs (-)	Total																
Prognosis			Other	Cancers LV64.70	2000	G664	GL6470	LL68.8, LY68.8	AA100	AA100		AA67.3	EE64.2	1L64.6	EK67.90	IM67 70	0.750	EG65.9	AP65.9
Prognosis	Total (homo)		Other	cancers															
Prognosis	Total (+)	() () ()	Other	cancers												-			
Prognosis			Stomach	W777.8	7,705.7	LL77.8		FY7630	AA80	AA80		EE/0.8	DD76	LL85.7	EK69.4	17100	8 0255	80200	PP70.8
Prognosis	Total (homo)		Stomach																
Prognosis	Total (+) vs	()	Stomach								-								
Prognosis			Total	LV67.4	EV68 2	GL67.3		FF68	AA85.7	AA85.7	7 1077	5.702.3	DD68.5	LL85.7	EK68.6	1100	DG66 9	EG66.9	AP66.9
Prognosis	Total (homo)		Total																
Prognosis	Total (+)	vs (-)	Total										1						
	Equivalence			8L=8V=9F =11G=11I		G=L			A=V					651=65 <u>L</u>	E				
		į,	Diversity	^]	FHY	ថ		FLY	٩٨	ADE	AF	JE C	1	111	X	 	DG	EG	АР
		9	5	арр8	app9	app11	36.1.1	appso	аррзб	арр55	app56	app57	10000	арроэ		-		арр85	
				37	38	4	73	Š	8	<u>*</u>	+	98				}		114	

Fig. 62

			Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis Prognosis	Prognosis	Prognosis	Prognosis	Treatment	Treatment	Treatine
		Equivalence	Total (+) vs (-)	Total (homo)		Total (+) vs	Total (homo)		Total (+)	Total (homo)		Total (+)	Total (homo)	All cases
go	Diversity		Total	Total	Total	Stomach	Stomach	Stomach	Other	Other		Vs (-) Total	Total	,
116 app87	¥				MV/66 0			+	cancers	cancers	cancers			
125 app96	좄				KK100			MIN CO.			MV65.9			
199 app170	Ŀ				1100			300			TEE 3			
207 app178	LM				M70.6			MM75			1 03.3			
								CAMIN			LIM/0.3			
Overall					D DQVV(5)			/ / / / / /						
Progno	than 3,			-	2			ארנין 5)						
sis							_	 5						
	survived													
					-			+	+					
					+				+					
		_	_	_	_	_	_	-		_				

Fig. 63

d G	Metastases		,				#	AE44 8, AA1	0						
d	Category (rate of	matignancy)	VV95.2, 11.89.60	#	VV95.2.1L189.60					W983, L189 6 O			VV95.6, III66.70	00000 7 0000	EE92 1 GG87 60 VV92 1 MM87 60
Treatment Effect	Other cancers		no adjuvant therapy (1 V)	no adjuvant therapy (FY)	no adjuvant therapy(GL)	Chemotherany (1 V)	(La) Ademonical de la constanta de la constant	no adjuvant	nerapy DE(75.3) no adjuvant therapy AE(74.6)	no adjuvani therapy DE (76.8)	no adjuvant therapy IL(100)	no adjuvant therapy EK(71.7)	no adjuvant	therapy MV(79)	
Treatment Effect	Total (homo)	Other cancers	no adjuvant therapy Vhetero (-)>homo	no adjuvant therapy Fhetero, homo>(+), no adjuvant therapy H(-	//neterozhomo no adjavant therapy Ghetero,homo>(-), no adjavant therapy L(-	OHIOH A GIRL		no adjuvant therapy	onestrock. Inone no adjuvant therapy Aheterock. Jhomo no adjuvant therapy Eheterock.	J,homo no adjuvant therapy Dhetero (-)>homo, no adjuvant therapy	Energio, homo>(-) no adjuvant therapy hetero>homo, no adjuvant therapy Lhetero, homo>(-), no adjuvant therapy E(-)), hetero>homo, no adjuvant	nerapy inereconomos(-)	no adjuvant therapy	Vhetero,(-)>homo	
Treatment Effect	Total (+) vs (-)	Other cancers		no adjuvant therapy F(+)>(-)	no adjuvant therapy G(+)>(-)				no adjuvant therapy A(+)>(-)	no adjuvant therapy E (+)>(-)	no adjuvant therapy L (+)>(-)	no adjuvant therapy K(+)>(-)			
Trealment Effect	Stomach cancer			Immunotherapy FY(67 1) FF(65)		Chemotherapy (FF)	Chemotherapy (VV)					no adjuvant therapy EK (85.4), Immunotherapy KK (58.3)	Chemotherapy MV(64)		
Treatment Effect	Total (homo)	Stomach	,	Immunotherapy H(-),(homo)>hetero			Chemotherapy A(-),(homo)>hetero, Chemotherapy Vhomo,((-)>hetero	Chemotherapy At-				.	Chemotherapy (-),	וחווח/בוופנפות	
핑	(-) Sy	Stomach		Immunotherap y H(-)>(+)								immunotherap (r. 1) (r.	- C - C - E		
		Diversity		F I	פר	FLY	۸۸	ADE	AE	DE	긤	丑	\MI	DG	AP
		d g		арро	app11	app35	аррзб	арр55	арр56	app57	арр65	арр69	app76		

		Treatment Effect	Trontmont Effect						
		Total		reament check	Treatment Effect	Treatment Effect		ል	8
		1 Utal (7) VS (•)	l otal (homo)	Stomach cancer	Total (+) vs (-)	Total (homo)	Other cancers	Category (rate	Metastases
d d	Diversity	Stomoch						of malignancy)	
ann87	MV	Collidati	Stomacn		Other cancers	Other cancers			
	<u> </u>			-				W92.1,	
appde	KB							MM87.60	
200	12								
app170	Ė				•••••••••••••••••••••••••••••••••••••••				
app178	Σ								
					• • • • • • • • • • • • • • • • • • • •				
Overall	More than								
Prognosis	3. all								
,	survived								
								***************************************	***************************************

0	שט	Age 50 (ratio, -49)							#	AA45.5, AE15.6.0	#			KK23 9, EE17, 50			
OP	<u> </u>	Smoking											EV69 E 10/20 20	UNDO DI NODI 30			
			DIVERSITY		FHY	- OF	FLY	AV	ADF	AE	DE		EK	- IMA	DG	EG	АР
		DP		арр8	арр9	app11	app35	app36	app55	app56	app57	app65	app69	app76	app84	app85	app86

Fig. 65

Fig. 66

		DP	DP	
		Smokina	Age 50 (ratio -49)	
DP	Diversity		(2: (2::-) 22 25:-	
app87	MV			
app96	KR			
app170	L			
app178	LM	#		
Overall Prognosis	More than 3, all			
	survived			

٢	Τ	T	T			Т	T	П						Т	T	-T			
Treatment Effect	Total (+)	vs (-) Total		no adjuvant	therapy D(-)>(+)		no adiuvant	therapy S(-)>(+)		no adjuvant therapy ((=)>(+)		no adjuvant therapy Y(+)>(-), immunotherapy	1(1)2(1)					Immunotherapy	H(+)>(-)
Promosis	Other	cancers		DD87.5		90	SS87.5	0400	SS100,	LL87.5	PS65.3	LY7080	AACES	70	LR67.20		Тб3.4	SY100	DV65.3
Prognosis	Total (homo)	Other	cancers									Ynatero>(-)			Lhatero (-)>homo Rhetero ho	1-)-011			
h		Other	cancers									(+)>(-)			R(+)>(·)				
22	Stomach			DG67.7		INAZEO	ST67.7			LV67.7	PS69.4	LY720	AC68 A	1 M72 4	RR68.1		8177.8	HS100	IY83.3
Prognosis	Total (homo)	Stomach						Capada	A Lander										
Prognosis	Total (+) Vs	Stomach						(+)<(-)	41713										
Prognosis	Total			GG66.7		IIBO	TT66.7	11.80	SS80	6.99	PS68	1.771.60	AA67	LM70.1	LR67.4		ST68.2	SY75	DY68
Prognosis		Total										Yhetero>(-)							
Prognosis	Total (+)	Total										Y(+)>(-)							
	Equivalence										3P=3S=9L =37D			V=N	L=R		28S=28T= 30S=371=4 6V=46E=4 7F=47Y=5 2P=52L=5 5L		
+		Diversity	AS	DG	┼	Σ		LPS	2	۲۸	S.	FLY	AG	ГМ	<u>ج</u>	GLY	TS.	HSY	DIY
		g	aqp_27	aqp_21	44	adb 9		aqp_5	7 400	4-dh 4	adba	афр9	agp13	aqp14	aqp23	aqp26	aqp28	aqp30	aqp37
				12		24	27	28	oc.	67	જ	14		8			09	62	69

Γ	Τ	, T		-	T	-	T	Т	T	<u> </u>		T								T	Т		_	1	_		T	Ť
Treatment Effect	Total (+)	vs (-) Total												no adjuvant therapy	Chemotherapy E(+)>(-)	Immunotherapy	no adjuvant therapy	V(+)>(-) Chemotherapy	V(+)>(-), Immunotherapy	(+)<								
Promote	Other	cancers	1000	AV04.7	EG04.2	VV63.4	1 103.4	FF03.4	UC64.9	LP65.8		SV80		DE670			1/670			067270	AA700			AS100	LV66.4	RR82.7	10.64.9	AG80.90
Prognosis	Total (homo)	Other	cancers							Lhetero.(-	Phetero, ho	(-) voisi		Ohetero (- I>homo.	Ehetero>ho mo>(-)		Ihetero<(-)>homo Vhetero,ho	(-)<-0)	Ehetero (-	Dhetero (-	Johnmo. Eheterooho	mo>(-)					
Prognosis	Total (+)	Other	cancers							P(+)>(·)				E(+)>(-)			V(+)>(-)											
Prognosis	Stomach		7 1001	LCGB 6	EV77 8	EV77 8	0777	1 069 5	L400.3	LP68.4		AS100		DE77 00			17720			GR69.6	KT83.3		0001	AE83.3	LV/1.5	K1/2.4	1/68 5	EG76.1
Prognosis	Total (homo)	Stomach												Ohetero>(- Phomo,	Eheterosh omo>(-)		hetero>(-	Jahomo, Vheteroah Amas()	(Linearly)									
Prognosis	Total (+) vs	Stomach											1	E(+)>(-)			V(+)>(-)											
Prognosis	Total		7,000	EG67	EV68 2	FY68 2	1 P68 2	0066.5	I PIONO	LP67.20		AA84.70	, 66.40	UE/0.1			1770.10			GG68.10	AK1000		CUSSY	2000	DTEG 7	FERE 5	W66.5	AG67.8
Prognosis	Total (homo)	Total										Ahomo>(-	Photos	Phomo,Eh	etero>hom o>(-)		lhetero>(-	Vheterosh omos(s)										
Prognosis	Total (+) Vs (-)	Total									-		E(±)<()	E(+)>(-)			V(+)>(-)											
	Equivalence		A=V	E=G	E=V	F≃Y	52P=52L	L=Q	55P=55R	L=P			GED=GEE=	671=66V			۱=۷											
		Diversity	۸۷	EG	EV	FΥ	LPS	٥	LPR	<u>-</u>		ADSV	DE	3			≥			EGR	ADKT		AES	2	RT	EQ		AEG
		g	aqp38	aqp45	aqp46	aqp47	aqp52	aqp53	aqp55	adb26		aqp57	agpeg				adbe7			aqp70	aqp71		1	1	1	†	 	adb86
			2	1	28	9	8	8	87	88		8	8	}			8			102	103				t	t		118

				Prognosis	Prognocie	Drawnach	D. Contract		þ				
			Familyalonco	Total (±)	2000	electrical a	riogilosis	Prognosis	8	Prognosis	Prognosis	Prognosis	Prognosis
			Lymyalogica	Total (+)	l otal (nomo)	lotal	Total (+) vs	Total (homo)	Stomach	Total (+)	Total	Other	Total (+) vs (-)
	2	Discourie.		(2)			0			Vs (-)	(homo)	cancers	
	, 1	Civersity		lotal	Total		Stomach	Stomach		Other	Other		Total
199	agn87	\ \I								cancers	cancers		
	2					FY72.1			LY72.1		Fhetero,	FY75.90	Immunotherapy
121	adb89	GT				2 0000					OM04<(-)		Y(+)>(-)
122	0000	•				C.000.0			GT68.5			GG64.9	
140	Ocal Par					1166.5			IT68.5			1649	
140	adp116											27.21	
157	aqp125	AGS				V V Z Z			0 2200				
158	agp126			***************************************		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			52/5.3			GS72.5	
162	200130	90				HQ/1.4			0.7900			HQ71.5	
		5				QR66.9			RR68.2				Immunotherapy
	ann 140	ΔT											R(+)>(-)
100	20,					AA66.4			AT68.4			AA641	
66	adb16/	Ŧ				29HH			HD69 A			0.000	***************************************
214	3qp182	NS				SSERA		+	1000.1			5.0000	
217 6	3qp185	-				1000			NS58.4			SS64.1	
229	300197	SN				0.701			169.4			1165	
235 a	agp203	2				NSOS			NS69.4			NS65.3	
252 2	0000	07			+	c:/0/			170.7			W66.9	
	200000					RR66.5			HR68.5			RR64.9	
	17701	2				QQ66.5			HO68 5			00640	
200 a	aqp224	QR				OR70 1			7 0200			200	***************************************
						+			EN 12.1			אאיס	
	-	All		27.1.100									
		Survived		NAME NO NAME OF THE NAME OF TH			DQ74AS(3						

therapy D(- mo), no rapy finerapy S(- mo), no finerapy L(- mo), no finer			Total (homo)	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect
Dispusable Total Signature Signatu			(2000)	All cases	lotal (+) Vs (-)	Total (homo)	Stomach cancer	Total (+) Vs (-)	Total (homo)	Other cancers
17. AS 18. Considerant therapy D(- 18. Cons	~	Diversity	Total		Stomoch					
December	p 27	AS			Collago	Siomacii		Other cancers	Other cancers	
Pietero (normo), no adjuvant therapy (GGP7 8 therapy DC)-(-)-(-)-(-)-(-)-(-)-(-)-(-)-(-)-(-)-(2.21	DG	no adjuvant therapy D(-	no adjuvant	. no aditivant	no adjuvant therapy Of	ac administra			
NS Sep Sep Sep Sep Sep Sep Sep Sep Sep Se	-		>hetero (homo), no adjuvant therapy Ghomo>hetero ((-1)	therapy GG87.8	therapy D(-)>(+))>hetero,(homo), no adjuvant therapy	therapy GG92.6			
Name	0 10	AS				chomoshetero ((-))				
ST no adjuvant therapy St. LPS modivant therapy St. Index of the control of the	6	Σ								
LPS no adjuvant therapy LL Infinite and Phomo-hetero.(1) Infinite and Phomo-hetero.(2) Infinite and Phomo-hetero.(3) Infinite and Phomo-hetero.(4) Infinite and Phomo-hetero.(5) Infinite and Phomo-hetero.(6) Infinite and Phomo-hetero.(7) Infinite and Phomo-hetero.(7) Infinite and Phomo-hetero.(7) Infinite adjuvant therapy VV87.8 Infinite adjuvant therapy VV87.8 Infinite and Phomo-hetero.(6) Infinite and Phomo-hetero.(7) Infinite and Phomo-hetero.(8) Infinite and Phomo-hetero.(1) Infinite and Phomo-hetero.(1) Infinite and Phomo-hetero.(1) Infinite and Phomo-(1) Infinite and Phomo-hetero.(1) Infi	9	ST	no adjuvant therapy S(-)>hetero,(homo), no adjuvant therapy Thomoshetero (1,1)	no adjuvant therapy TT87.8	NIS S(-)>(+)	no adjuvant therapy S(-)-helero (homo), no adjuvant therapy	no adjuvant therapy TT92.6			
LY no adjuvant therapy L(ഹ	LPS	no adjuvant therapy Phomo>hetero.((-))	immunotherapy PP62	no adjuvant therapy L(-)>(+)	Inomo>hetero((-)) no adjuvant therapy Lhetero>(-), no adjuvant	no adjuvant therapy PP92.6	no adjuyant therapy L(-)>(+)		
PS	4	۲۸	no adjuvant therapy L(-)>hetero,(homo), no adjuvant therapy Vhomos-hetero (1-1)	no adjuvant therapy VV87 8		urerapy knomo-netero ((-) no adjuvant therapy adjuvant therapy	no adjuvant therapy W92.6			
FLY no adjuvant therapy (Themotherapy (Theoret page Theoret page Theo		PS		no adjuvant therapy SS(78)		Vhomo>helero.((-))		NI S(+)>(-)	no adjuvant therapy P(-), netero-homo, no adjuvant therapy	no adjuvant the SS(68.8)
AG LM LM LM LM LM LM LM L		FLY	no adjuvant therapy Yhetero homo>(-); immumotherapy Yhetero,homo>(-)	Chemotherapy LY(64.5) Immunotherapy YY (63.9)	Immunotherapy Y(+)>(-)		immunotherapy Y(62.9)	no adjuvant therapy Y(+)>(-) Chemotherapy Y(+)>(-)	Shomo,hetero>(-) Immunotherapy Fhetero,(-)>homo,no adjuvant therapy Thetero homo>(-),	no adjuvant the LY(75.1), Chemotherapy (65.8),
LR GLY GLY ST ST HSY Immunotherapy Hhetero>(-) Homo DIY DIY DIY DIY DY Chemotherapy Chemotherapy DY(78.2) Chemotherapy DY(62.5)	8	AG							: Cherrollerapy : Yhetero,home>(-)	immunomerapy (68.1)
LR GLY ST ST HSY Immunotherapy Hhetero-(c. fimmunotherapy Hytero-(c. f	-	3								
ST Immunotherapy Hhetero-(c. fimmunotherapy Hytero-(c. fimmunotherapy Hytero-(c. fimmunotherapy Hytero-(c. fimmunotherapy Hytero-(c.)), from him thereon HY(65.2) And hetero-(c.)), from him therapy YY(78.2), Chemotherapy Chemotherapy DY(62.5)	 	2								
HSY Immunotherapy Hhetero->(- immunotherapy Hhetero->(- immunotherapy Hhetero->(- immunotherapy Hhetero->(- immunotherapy Hhetero->(- immunotherapy Hhetero->(- immunotherapy Hy(65.2) Xhetero->(-),homo no adjuvant therapy YY(78.2), Chemotherapy DY(78.2), Chemotherapy DY(62.5)	T	\ \ \								
HSY immunotherapy Hhetero>c. immunotherapy Hhetero>c. immunotherapy Hhetero>c. immunotherapy Hy(65.2)	1	ST								
DIY no adjuvant therapy YY(78.2), Chemotherapy DY(62.5)	 	HSY	immunotherapy Hhetero>(-),homo, immunotherapy \text{\text{Thetero}>(-), homo	Immunotherapy HY(69 6)		Immunotherapy Hhetero>(-),homo, immunotherapy				
		DIY		no adjuvant therapy YY(78.2), Chemotherany		rnetero-(-),nomo		no adjuvant therapy Y(+)>(-)	no adjuvant therapy D(-),hetero>homo, no	no adjuvant ther
	1			DY(62.5)					adjuvant therapy Dhomo, hetero>(-)	

DQ Diversity aqp38 AV		Headildin Eliger	Effect	Treatment Effect	rearment Effect	Treatment Effect	Treatment Effect	Treatment Effect
	Total (homo)	All cases	Total (+)	Total (homo)	Stomach cancer	Total (+) Vs (-)	Total (homo)	Other cancers
	Total		Stomach	Stomach		Other cancers	Other cancers	
				Chemotherapy Ahetero>(-), homo Chemotherapy	Chemotherapy AV(65.2)	Chemotherapy A (+)>(+)	no adjuvant therapy V(-) hetero>homo, no adjuvant therapy	no adjuvant theraj AV(71.3)
aqp45 EG	***************************************			VIIETO 21:1 HOITO			Anamo netera>(-)	
aqp46 EV								
aqp52 LPS			+					
-				***************************************				
-						***************************************		
-								
aqp57 ADSV	immunotherapy Ahomo (all survived)>(-)	Immunotherapy AA		Immunotherapy	Immunotherapy AA(100)			
agob6 DF	no adimant therant Dhotore //	DOLL		Vhetero (-) >homo				
······································	in adjavani irei apy Driesero, (1.))-homo, Chemotherapy Dhetero, (), homo, immunotherapy Dhetero, ()-homo, no adjavani therapy Ehstero ((-))-homo, Chemotherapy Ehstero (-), homo, immunotherapy Ehstero (-), homo, immunotherapy Ehstero (-), homo.	no adjuvant therapy EE(77.7), Chemotherapy DE(62.1), immunotherapy EE(60.3)		Chemotherapy Dhefero>(-),homo, Chemotherapy Ehetero>(-),homo	Chemotherapy DE(65:1)		Chemotherapy Dhetero-((-), homo, Chemotherapy Ehetero.(homo)>(-)	Chemotherapy DE
aqp67 IV	no adjuvant therapy Ineterio.((-)) Chemotherapy Inetero-(-), homo Immunotherapy Inetero.(-)-homo, no adjuvant therapy Vinetero.((-))-homo, Chemotherapy Vinetero-(-), homo,	no adjuvant therapy IV(79.6) Chemotherapy DE(62.1) Immundtherapy		Chemotherapy Ihetero>(-),homo Chemotherapy Vhetero>(-),homo	Chemotherapy IV(65 1)		Chemotherapy Ineteru,((-))>homo, Chemotherapy Vhetero,(homo)>(-)	Chemotherapy IV
adp70 FGR	Immunotherapy Vhetero,homo>(-)	EE(60.3)						
 								Chemotherapy W
adp74 AFS								AU(41 /), Chemotherapy TI
†-								
╁								
			-					
aqp85 LV								
aqp86 AEG	Immunotherapy Ghetero>(-)>homo	Immunotherapy EG/78-2)	Immunot		Chemotherapy AA 70.6		no adjuvant therapy	no adjuvant thera

EG(80.8)

		Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect
		Total (homo)	All cases	Total (+)	Total (homo)	Stomach cancer	Total (+) Vs (-)	Total (homo)	Other cancers
g	Diversity	Total		Stomach	Stomach		Other cancers	Other cancere	
aqp87		Immunotherapy Yhelero>homo(-)	no adjuvant therapy FY(82.3), Immunotherapy	immunother apy F(-)>(+)	immunotherapy A(-)>(homo), Chemotherapy Fhomo>hetero(-)	Chemotherapy FF(81.3), Immunotherapy LY(68.1)		no adjuvant therapy Fhetero ()>homo	no adjuvant therapy FY(75) YY(75)
aqp89	GT		7 7 7						
aqp90	L	***************************************							
aqp116	2								
aqp125	AGS								no adjuvant therapy AS(73.7)
p126	ğ								7
aqp130	a R	Immontherapy Chetero>(-)>home, Immontherapy Rhetero>homo>(-)	Immunotherapy QR(75)						
aqp140	AT								
aqp167	ૠ								
aqp182	NS								
aqp185									
p197	SS		no adjuvant therapy SS(78)			NIS SS(70)	no adjuvant therapy S(+)>(-)	no adjuvant therapy N(-),hetero-homo, no adjuvant therapy	no adjuvani therapy Ss(68-8)
aqp203	<u>N</u>							Shomo hetero>(-)	
aqp220	H								
p221	욷				***************************************				
aqp224	aR								
	All								
	אוא נותפ								

Diagram 73

		DO	00	DO		
			3 0	בוב	בי	חת
		Cancer in Family	Category	Metastases	Alcohol	Smoking
DQ	Diversity					
aqp_27	AS					
aqp 21	DG					
aqp_10	AS					
adb 9	M					
aqp_6	ST					
aqp_5	LPS					
aqp 4	ΓΛ					
aqp_3	PS			#		
aqp9	FLY					
aqp13	AG		***************************************			
aqp14	ΓM			LL100,		
0000	-			LM23.20		
aqpz3	LK					***************************************
aqp26	GLY					
aqp28	ST					
aqp30	HSY			#		
aqp37	DIY					*
***************************************						+

Diagram 74

Q
caricer in Family
EE50, GG19.4 O
LQ26.4, QQ12.5.0
29.7 LR0.0
•
E026.4,
12.50
26.4, W12.5
GG94 4 FG82 8 O

Diagram 75

		DQ	DO	00	00	00
		Cancer in Family	Category	Metactacec	Alcohol	Sec. Aces
DQ	Diversity		(126222)	NICIO (COCO)	בור ה ה	BIIIONIIG
aqp87	FLY			YY50 11 20 O		
aqp89	GT	GT26.4, GG12.5		2017		
adb90	1					
aqp166	Δ			11100 11/23 2		
aqp125	AGS			SS100, AA20		
aqp126	HQ			2		
aqp130	QR		#			
aqp140	AT	AT26.8. AA12.2.0				
aqp167	Æ					
aqp182	NS	NS26.8. SS12.2.0				
aqp158	<u>L</u>	•				
aqp197	NS			#		DI66.7,
aqp203	2	#		W32 1122 2		2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
aqp220	HR	HR26.4, RR12.5 0				
aqp221	HQ					
aqp224	QR			RR100,		
				QR23.2 0		
	All survived					
				-	-	-

17		Total					
					Alfrasse		
	No. of Diversity	Total	Stomach	Other cancers	Treatment Effect	Stomach Cancer Treatment Effect	Other cancers Treatment Effect
	3		aGCGaGCG>				
_ I	3						
	<u></u> က	***			Immunotherapy: kaAakaAa>kAAGKAAG> kAAAKAAG	Immunotherapy: kAAAkAAA>kAAGkAAG>	no adjuvant therapy: kAAAKAAG>KAAGKAAG
	3		***************************************			KAAAKAAG	
	2						
	υ						
	4		hCACeGAA>				
ļ	3		OCOOCC.				
ł					-		no adjuvant therapy:
1	7	+					איניאליאי איניאליאלי
	2			dGACdGAU>			no adjuvant therapy: dGACdGAU, dGAUdGAI>dGACAGAC
I				aGAUdGAU			Chemotherapy: aGCCaGCU>aGCCaGCU
	ဖ			eGAGaGCC>	no adjuvant therapy: aGCCaGCC>aCGUaGCU,		acceaecovaecceaece
				eGAGaGCU	Chemotherapy: aGCUaGCU, aGCGaGCG,		
-	3				accorded to the second	no adiiwant theraw:	
	Ŋ		rCGGrCGG>		no adjuvant therapy: rCGCrCGG>rCGGrCGU	no adjuvant therapy: rCGCrCGG>rCGGrCGU	
f						Chemotherapy: rCGGrCGU, rCGGrCGG,	
i	3				Chemotherson, villACyllAC, villAllAll	roecrcee>roecrcec	
ı	2				Chemically, your your your		Chemotherapy:
1	2						
		-					

leic No. of Total Diversity 2 2 3 aGCAaGCC> 2 2 2 2 2 2 3 aGCAaGCA 3 3 aGCAaGCA 3 3 aGCAaGCA 2 2 2 2 2 2 3 3 3 3				
No. of Total Diversity 2 2 3 aGCAaGCCA 2 2 2 2 2 2 2 3 aGCAaGCCA 3 3 aGCAaGCCA 4 aGCAaGCCA 5 aGCAaGCCA 6 aGCAaGCCA 6 aGCAaGCCA 7 aGCAAGCCAAGCCA 7 aGCAAGCCAAGCCAAGCCAAGCCAAGCCAAGCCAAGCCA		All cases	Stomach Cancer	Other cancers
2 2 2 2 2 3 2 2 3 3 2 3 3 3 3 3 3 3 3 3	Stomach Other cancers	Treatment Effect	Treatment Effect	Treatment Effect
2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2				
2 3 2 2 2 2 2 3 2 2 3 2 2 3 3 2 3 3 3 3				
0 3 5 5 3 5 5 5 6				no adjuvant therapy: vGUGvGUG, vGUAvGUG>
0 0000000000000000000000000000000000000			***************************************	YOUNGO!
2 3 2 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		• diamen	-	
		no adjuvant therapy:		no adjuvant therapy:
		rCGGrCGG> rCGArCGA		rceercee,rceArcee>
				rcgarcga
	tACAMAUG>			
2				

	Smoking	P 1										***************************************									
	Metastases																				
	Alcohol								eGAGeGAG(55.6).	eGAAeGAG(0),	eGAAeGAA(16.7)	***************************************									
	Cancer in Family																rCGGrCGU(50),	rCGCrCGG(40), rCGCrCGC(0)			
	No. of	Diversity	က	3	5	3	2	5	4			က	2	7	9	က			က	2	C
DR R	Nucleic	Acid	-16	4	12	14	19	26	28			34	53	25	58	69	72		78	06	20

		Metastases		vGUCvGUC(33.2),	vGUCvGUU(23.5),	vGUUvGUU(42.9)												
		Alcohol																
		Cancer in Family																
	 +	Diversity	2	 I	70 4	2	18	0	2	2	2	2	က	2	2	က	2	
DR		Acid	 			101	104	106	112	117	145	152	166	169	179	181	206	

	Stomach Cancer	Treatment Effect		no adjuvant therapy:	בייייייייייייייייייייייייייייייייייייי	Same curve as DQ_23	Page page of procedure of procedure																	
	All cases	Treatment Effect									Immunotherapy: vGUAvGUG,	vGUGvGUG>vGUAvGUA												
	Other concorn							tACGIACC,	2000				ag: Aag: Sac	account accoun				DAACDAAC DAACBAATIS		HCCHCG,	tACGtACG>tACCtACC	VGUAVGUG, VGUGVGUG>	VGUAVGUA	
Total	Total Stomach																					-		
DR	eic	Acid Diversity -29	-23 2		-15 2	00NP19	2	3	DQNP25 2	JQNP27			DQNP38 3	QNP47 3	DQNP48 2	QNP49	DQNP57 6		DQNP72 2		NOND78	7	2NP91 2	

	Common Common	Treatment Effect													
		Treatment Effect Tr													
	!	Other cancers													
al		al Stomach				-									
Total		Diversity 1 otal	2	3	4	2	2	2	2	2	2	2	2	2	2
DR	Nickein			DQNP135	DQNP140	DQNP147	DQNP150	DQNP154	DQNP169	DQNP191	DQNP210	DQNP213	DQNP215	DQNP218	DQNP235

DR						
		Other cancers				
Nucleic Acid	No. of Diversity	Treatment Effect	Cancer in Family	Alcohol	Metastases	Smoking
-29			,			
-23	2					
-15	2					
DQNP19	2	no adjuvant therapy:				nAACnAAC(54.7), nAACnAAU(59.8)
		nAACnAAC, nAACnAAU>				nAAUnAAU(39.1)
DQNP 21	က	no adjuvant therapy:				
DQNP25	2					
DQNP27	2					
DQNP35	2					
DQNP38	က	Chemotherapy: aGCAaGCG>				
DQNP47	က					
DQNP48	2					
DQNP49	က					
DQNP57	9					
DQNP62	2					
DQNP72	2	The Same curve with DQ19				rCGArCGA(39.1), rCGrCGG(59.8).
		rCGGrCGG,				rcgGrcGG(54.7)
DONP77	4	Chemotherapy				
	r	Chemotherapy. rAGGrAGG>rAGArAGG, rAGArAGA				
DQNP78	2					
DQNP91	2				ICUGICUG(39.7), ICUGIUUG(26.8), IUUGIUUG(31.8)	
DQNP93	2					
DQNP94	2					

		Bui																			
		Metastases Smoking		dGACdGAC(32.6), dGACdGAU(27.1),	dGAUdGAU(34.4)			ICUCICUC(47.8),	JCICUU(24.5), ICUUICUU(32.1)			dGACdGAC(32.6), dGACdGAU(27.1),	AUdGAU(34.4)				CICUC(32.6),		COUNTY C	GICUG(32.1)	
		Alcohol		9 9		tACCtACU(21.3),	(5.03)	0	0			9 9 	99		ICUCICUC(50), ICUCICUG(18.6),	ICUGICUG(22.5)	<u>ਹ</u> ਹੁ	3 -	<u>ੇ</u>	2	
-		Cancer in Family				***************************************													*************		
	Other cancers	l reatment Effect			no adjuvant therapy:	aGCCaGCC>aCGUaGCU Immunotherapy:	tACCaGCU>tACCaGCC														
	70 ON	No. of Diversity	2	m	4			2	2	2	2	i	2	6	J	6	4	7		2	2
DR	Nicloid	Acid	DQNP118	UQNP135	DQNP140			14/	DQNP150	DQNP154	DQNP169		DQNP191	DONP210		DONP213		DQNP215		DQNP218	DQNP235

. , Diagram 84

DP		Total					
					All Cases	Stomach Cancer	Other cancers
Nucleic Acid	No. of Diversity	Total	Stomach	Other cancers	Treatment Effect	Treatment Effect	Treatment Effect
98	2	All same with the survival curve					
107	2	All same with the survival curve					
118	2	All same with the survival curve					
167	. 2	All same with the survival curve					
179	2	All same with the survival curve					
				 		<u> </u>	
		All NS					

Position		D	iverse /	Amino	Acid		no adjuvant therapy	Chemotherapy	Immunotherapy	
_29	M						M	M	M	<u> </u>
_28	M						М	M	M	
27	V						V	V	W	
26	<u> </u>						L	i i	L	
25	Q						Q	Q	Q	-
_24	V						V	V	V V	
_23	S			1. –			S	S		
_22	A						A	Ä	S	
21	Α						Ä	Ä	Α	
20	Р						P	P	Α	
_19	Q						R	+	P	
_18	T			+-		+	T	R	R	
17	V						\ \ \ \ \ \ \ \	T	T	
_16	Α		1	1		+		V	V	
_15		+	+ -	+			A	Α	Α	
_14	1 - 1 -	+				+	L L	L	L	
13	A	+	1				Т	T	Ť	
13	L	+	+				A	Α	Α	
11	+ -	+	+				L	L	L	
10	М	+	+		_		L	L	1 - 1	
9	T M	 	 				M	M	M	
			 				V	V	V	
8	 	-	├	 			L	L	 	
7	<u> </u>	-	ļ				L	L		
6	T						T	Ī	 	
5	S	<u> </u>					S	S	S	ļ
_4	V		L				V	V	V	
3	V	1					V	v	V	
2	Q						Q	à		
1	G				1		G	G	Q	
1	R					T	R	R	G	
2	Α						Α	A	R	ļ
3	T						T		A	
4	Р						Р	P	<u>T</u>	
5	E					 	E		Р	
6	N						N	E	E	
7	Υ						Y	N	N	
8	L	V			+		L or V	Y	Υ	
9	F	Н	Υ		 			L or V	L or V	
10	Q		-		-		0	0	0	DP8 LV and DP F
11	Ğ	L			 	 	Q	Q	Q	
12	R				 		G or L	G or L	G or L	
13	Q				 		R	R	R	
14	E				+		Q	Q	Q	
15	c						E	E	E	
16	Ÿ				 		С	С	c	
17	A						Υ	Y	Y	
18	F						Α	Α	A	
19	N	+			-		F	F	F	
20	G				1		N	N	N N	
21	T						G	G	G	
22	à		$-\!\!-\!\!\!\!-\!$		1		T	T	T	
23	R						Q	Q	Q	
24	F						R	R	R R	
25							F	F	K	
26							L			
27	E						E	E	L	
41	R						R	R	E R	
28	Y						Ÿ			

Position		(Diverse	Amino	Acid		no adjuvant therapy	Chemotherapy	Immunotherapy	
29							1	1		
30	Y						Y	Y	Ÿ	
31	N					\neg	N	Ň	N	
32	R						R	R	R	
33	E		_	1-			E	E		_
34	E		1				Ē	E	E	
35	F	L	Y	-	+		0	0	E	
36	Α	1 V	 	 		+	A or V		0	
37	R	 -	 	1	+		R	A or V	AV	ļ
38	F		 				F	R	R	<u> </u>
39	D		+	+				F	F	
40	S		+	+			D D	D	D	
41	 	 					S	S	S	
42	V	+	┼		ļ		D	D	D	
		+					V	V	V	
43	G		ļ				G	G	G	
44	E						E	E	E	
45	F				J		F	F	F	1
46	R						R	R	R	
47	A		<u> </u>				Α	Α	A	
48	V			1			V	V	V	
49	T				1		T	T	T	
50	E		T		1		E	Ē	Ė	
51	L			T	1		1 - [
52	G				<u> </u>		G	Ğ	L	
53	R		1	†	+		R	R	G	
54	P	 	 	 			P	- K	R	
55	A	D	E	 	+	+		Р	Р	
56	A	E	┼─┶─	 	+		AD	0	0	
57	D	† E	 	 	+		0	0	0	
58	Y	 	 			-	0	DE	0	
59	w		 		 		Y	Υ	Υ	
60	N			 			W	W	W	
61	S		-	<u> </u>			N	N	N	
62	Q	 	├	 	ļ		S	S	S	
63			<u> </u>		_		Q	Q	Q	
	K	ļ			 		K	K	K	
64 65	D	ļ	ļ				D	D	D	
	F		L		<u> </u>		IL .	l or L	l or L	
66	<u> </u>			<u> </u>			L	L	L	
67	E						E	E	E	
68	E						E	E	E	
69	E	K					EK	E or K	E or K	
70	R						R	R	R	
71	Α						Α	A	A	
72	V						V	v	v	
73	P						Р	P	P	
74	D						D	D		
75	R					†	R	R	D	
76		М	V				0		R	
77	С					 	c	0	IM	
78	R					 -	R	C	С	
79	Н					1	H	R	R	
80	N					┼ ┼	N	Н	Н	
81	Y					 	Y	N	N	
82	E					 	- <u>-</u> - +	Y	Υ	
83	ī					 	E	E	E	
84	D	G	+			 	L	L	L	
85	E	G				 	0	DG	0	
							0	EG	0	

Position		Di	iverse A	mino A	oid .		no adjuvant therapy	Chemotherapy	Immunotherapy	
86	Α	Р	I		I		0	0	0	
87	М	V					Ö .	MV	0	
88	T						T	T	T	
89	L						L	L	L	
90	Q						Q	Q	Q	
91	R		1				R	R	R	
92	R						R	R	R	
93	V					Ī	V	V	V	
94	Q						Q	Q	Q	
95	Р						P	Р	Р	
96	K	R					0	0	0	
97	V						V	٧	V	
98	N						N	N	N	
99	٧						V	V	V	
100	S						S	S	S	
101	P					1	Р	Р	Р	
102	S						S	S	S	
103	K						K	K	К	
104	K		1				K	K	К	
105	G		 			i	G	G	G	T
106	P						P	Р	P	1
107	L			 	 	†	L	Ĺ	Ĺ	<u> </u>
108	Q						Q	ā	Q	<u> </u>
109	Н			-		t	Ĥ	H	H	· · · · · · · · · · · · · · · · · · ·
110	Н				-	 	H	Н	H	
111	N				 	<u> </u>	N	N	·N	
112	L		 				L L	Ĺ	L L	
113	L			 -		-	<u> </u>	Ĺ	Ī	
114	V					 	· v	v	V	<u> </u>
115	C						č	Ċ	Ċ	
116	Н		<u> </u>			 	H	Н	Н	
117	V					 	V	v	V	
118	T						Ť	Ť	Ť	<u> </u>
119	D	· · · · · ·		·		-	D	D	Ď	
120	F					 	F	F	F	1
121	Υ						Y	Y	Y	
122	Р						P	P	P	-
123	G			i			G	G	G	
124	S						S	S	s	1
125	1						I	1	ī	1
126	Q						Q	Q	Q	
127	V			T	l		v	V	v v	1
128	R		l	Γ	i —		R	R	R	†
129	W						Ŵ	W	Ŵ	1
130	F						F	F	F	1
131	L				T		Ĺ	L	L	
132	N						Ñ	N	N	1
133	G						G	G	Ğ	
134	Q						Q	Q	Q	
135	Ē						E	E	E	
136	E						E	Ē	E	
137	T						T	Ť	T	
138	Α						Ā	Ä	Ä	
139	G						G	Ĝ	G	
140	V						v	v	V	
141	V						V	v	V	1
142	S						Š	S	S	
										1 3
143	T	ı					T	Т	Т	

Position		D	iverse A	mino A	cid		no adjuvant therapy	Chemotherapy	Immunotherapy	
145	L	T	I		T		L	L	L	
146	1	1		1			ı		T	
147	R						R	R	R	
148	N						N	N	N	
149	G						G	G	G	
150	D	1	1				D	D	D	
151	W	1				 	W	W	W	
152	T					1	Т	T	Т	
153	F	1			1	1	F	F	F	
154	Q				1	1	Q	Q	Q	
155	1						1	ı	1	
156	L					1	L	L	L	
157	V	t				1	V	V	V	
158	М					1	M	М	M	
159	L		 			1	L	L L	†	
160	Ē	 	 	 	1	1	Ē	E	E	
161	М	 	†	<u> </u>		 	M	М	M	
162	T	 	 	 	 	 	T	T	T	
163	P	1	 	-	1	+	P	P	P	
164	à	 -	 	 	+	 	i a	i a	i a	
165	à	 	 	 	 	+	Q	a	à	
166	Ğ	 			 	+	G	Ğ	Ğ	ļ
167	Б		 		 	 	D	D	D	
168	V	} -	+		 	+	V	V	V	
169	Y	├	 		 	+	Ÿ	Ÿ	Ÿ	
170	i	 	 	 	 	 	0	0	0	
171	Ċ	 		 	+	 	Ç	Č	C	-
172	à				 	+	Q	Q	Q	
173	v		 		 	+	V	V V	v v	
174	E	 			 	+	E	E	E	
175	Н		 	 		+	 	H	H	
176	Ť		 	 	-	 	T			ļ
177	s		 		 	 	s	T	T	
178	L	М		ļ	 				S	
179	D	IVI .	 		 -	ļ	LM	0	0	ļ
180	S	 	 	 	 		D	D	D	ļ
181	P	 	 	 	 	 	S P	S	S	
182	V				<u> </u>	 		Р	Р	
183	T		 	 	 	┼	V	<u> </u>	V	
				├	<u> </u>	 	Ţ	Ţ	Ţ	<u> </u>
184	V E			 		 	V	V	V	ļ
185 186	W	 	-		 		E	E	E	ļ
	VV	<u> </u>		ļ	ļ	ļ	W	W	W	
187	K	-	ļ			ļ	K	K	K	ļ
188 189	A				<u> </u>	 	A	A	A	
	o ,	 	 	-	 -	 	Q	Q	Q	ļ
190	S 	 	-	 		 	S	S	S	
		 	ļ	ļ		ļ	D	D	D	
192	S	ļ	 		<u> </u>		S	S	S	
193	A		<u> </u>	<u> </u>			A	A	Α	
194	R			 	ļ		R	R	R	
195	S	L			ļ <u> </u>	ļ	S	S	S	
196	K			<u> </u>		ļ	K	K	K	
197	Ţ		 	ļ		ļ	T	T	T	
198	<u>L</u>					<u> </u>	<u> </u>	L	L	
199	Ţ		<u> </u>				T	T	T	
200	G		ļ			ļ	G	G	G	
201	A						Α	Α	Α	
202	G						G	G	G	
203	G					L	G	G	G	

Position		Diverse Am	ino Acid	no adjuvant therapy	Chemotherapy	Immunotherapy	
204	F			F	F	F	
205	٧			V	V	v	
206	L			L	<u> </u>	L	
207	G			G	G	G	
208	L			L		L	
209					<u>_</u>		
210	1					 -	
211	С			Ċ	Ċ	c	
212	G			Ğ	Ğ	G	
213	V			V	V -	V	
214	G			G	Ğ		
215	1					G	
216	F			F	F		
217	М			M		F	
218	Н				M	M	
219	R			H	Н	H	
220	R			R	R	R	
221	S			R	R	R	
222	ĸ			S	S	S	
223	K		-+	K	K	K	
224	v -		-+	K	K	K	
225	à			V	V	V	
226	R			Q	Q	Q	
227	G	_		R	R	R	
228	S			G	G	G	
229				S	S	S	
229	Α			Α	Α	A	

"or" – expected to be the same antigen

32 31 30 29	М						adjuvant therapy			
_30 _29							M	М	М	
_29	S						S	S	S	
29	W						W	w	w	
	K						K	К	K	
_28	K						K	K		
_27	Α	S					0		K	<u> </u>
_26	L			_		+	- 	0	0	
_25	R			+-			R	R	<u> </u>	
_24			+ -			+			R	
_23	Р	1				 -				
_22	G	+	+	+-		-	P	Р	P	
_21	D	G	_	+			G	G	G	
20	+ =			-			GG	()	GG	
19	R	+	+	+-			_ L	L	L	
19							R	R	R	
18	A	V					0	0	0	
_17	A						Ă	Ä	A	-
16	T					T	T	T	÷	
15	V						V	v	V	
14	T			1	T		 	T		
_13	L				\top	1	1 t 1	L	<u>T</u>	
_12	М			 		+	M		L	
_11	L		T	1		+	L	M	M	
_10	Α	S	 	 				<u>L</u>	L	
_9		M	+	+		+	0	0	0	
_8	Ĺ	 '''	+	+	+		0 1	0	0	
7	s	 	+			+	<u> </u>	L	L	
_6	S	T	 		+		S	S	S	
5	L			 			TT	0	TT	
3		P	S	 			0	0	PP	
	L	V					L W	0	W	
3	Α		L				Α	Ă	A	
2	E						E	E	É	
1	G						G	G	G	
1	R						R	R	R	
2	D						D	D	D	
3	Р	S				T	SS	PS	PorS	
4	Р						P	P		
5	E						E	E	Р	
6	D					1	D	D -	E	
7	F						F	F	<u>D</u>	
8	V						 		F	
9	F	L	Y		 	 		V	V	
10	Q		-				0	LY	YY	DQ3 PS is same as DQ9 L
11	F					 	Q	Q	Q	
12	K				 		F	F	F	
13	A	G					К	K	K	
14	- 2	M			ļ		0	AA	GG	
15	c	IVI					L or M	L or M	LM	
16	Y						C Y	С	С	
17	F						Y	Y	Y	
18	+						F	F	F	
19	N						T	T	F T	
20	N +						N	N	N	
20	G				7		G	G	G	
21	Ţ						T	T	G T	
22	E		[E	E		
23	L	R					LR	LorR	E	
24	V	T					V	V	RR	
25	R						R	R	V	
26	G	L	Υ				0		R	
27	V						- v -	0 V		

Position	I_{-}	Div	/erse	Amin	o Acid	no adjuvant therapy	Chemotherapy	Immunotherapy	
28	S					S or T	S or T	S or T	
29	R		_			R	R	R	
30	Н	S	_ Y			НН	0	HY	
31				T			Y	1	
32	Υ					Y	Ÿ	† †	
33	N	1		T-	1	N	N		
34	R	1	_	1-	+ -	R		N	
35	E			+	1	E	R	R	
36	E		+-	+-	+		E	E	
37	늄		TY		+-+	E	E	E	
3,	"	1'	'		1 1	YY	DY	0	DQ28 ST is same as
38	A	V	+-						DQ37I
39		 -∨	+-		1	A or V	A or V	A or V	
	R	-	-	+	1	R	R	R	
40	F	-	—	┵		F	F	F	
41	D	1				D	D	D	
42	S	<u> </u>		<u> </u>	L1	S	S	s	
43	D			1	1 1	D	D	D	
44	V			T -		V		† - V	
45	E	G	T	1	1	E or G	EG EG		
46	E	V	\top	—	1 1			E or G	
	1		1	1	1 1	0	0	0	DQ28 ST is same as
47	F	TY	+	+	 				DQ46VE
	-	1.	1	1	1 1	0	0	0	DQ28 ST is same as
48	R	+-	+	+	 			<u> </u>	DQ47FY
49	A	+	+	 	 ⊦	R	R	R	
50	₩ ÷	+	+-	 		Α	A	Α	
51		 	+-	↓		V		V	
	Ţ	 _	-	<u> </u>			Т	T	-
52	L	P	1]	1 1	0	0	0	DQ28 ST is same as
							V	1 '	DQ52PL
53	<u> </u>	Q	<u> </u>	<u>L</u> .		LL	L or Q	L or Q	BQ32FL
54	G		<u> </u>			G	G	G	
55	L	P	R			P or R	P or R		5-5-5
	Ĺ			li		1	FULK	P or R	DQ28 ST is same as
56	L	Р				LP	PP		DQ55L
57	A	D	S	V		0		L or P	
58	Α					T A	0	AA	
59	Е	_	_				A	Α	
60	Y			-		E	E	E	
61	w	<u> </u>				Y	Υ	Υ	
62	N					W	W	W	
63	S					N	N	N	
64	a					S	S	S	
65		_				Q	Q	Q	
66	K					K	K	K	
	D	Ε				DE	DE	EE	
67	ᆜ					IV	IV	W	
68	ᆜ				T	L	L		
69	E					E	Ē	L	
70	E	G	R			0		E	
71	Α	D	K	T		0	0	0	
72	R			-		R	0	AT	
	A			$\neg +$			R	R	
	A	E	s	-+	- +-	A	Α	Α	
75	i l	$\overline{\nabla}$	 +			ES	0	ES	
	5	 +	\dashv	-+	\rightarrow	LV	0	0	
	Ř	T	\rightarrow	\dashv		D	D	Ď	
	\(\)	' +	\rightarrow			0	0	RT	
	c	\dashv	-+			V	v	V	
, ,	R	-+	\rightarrow	-+		С	С	C	
80	 	-+	$-\downarrow$			R	R	R	
80	-					Н	Н	<u>r</u>	
80 81			- 1	[N	N	Н Н	
80 81 82	N							N	
80 81 82 83	N Y								
80 81 82 83 84	N Y E	Q	\exists	\dashv	-	Y	Υ	Υ	
80 81 82 83 84 85	N Y E	V	#	+		Y	Y 0	Y QQ	
80 81 82 83 84 85	N Y E L	V	G			Y	Υ	Υ	

Position			Diverse	Amino	Acid		no adjuvant therapy	Chemotherapy	Immunotherapy	
87	F	L	TY				FY	0	LY	
88	R						R	R		
89	G	T					TT	0	R	
90		T		-	 		ŤŤ		0	
91	L	 		+			 		- 0	
92	a	_	+-					LL	L	
93	R		+	+			Q	Q	Q	
94	R		+-			-	R	R	R	
95	T V	+	+				R	R	R	
96	E		-				V	V	V	
			-				E	E	E	
97	P	_			J		Р	Р	Р	
98	T						T	T	T	
99	V						V	V	v	
100	T						T	Ť	T T	
101	I	7					i	 		
102	S		1	1	+	+-	S			_
103	P		1	+	+			S	S	
104	S	+	+	+	+		P	Р	Р	
105	R	+	 				S	S	S	
106		+		 			R	R	R	
	<u> </u>	 				1	Т	T	Т	
107	E						E	E	E	
108	Α						Α	A	Ā	
109	L						L	L	1	
110	N				1		N	N		
111	Н				+		Н		N	
112	Н			 	+	+		Н	Н	
113	N	1	 	 			H	H	H	
114	 	 	 	 	 		N	N	N	
115	 [-	+	+		├		<u> </u>	L	L	
116	1	\ \ \	+		 		L	L	L	
117		<u> </u>		<u> </u>	<u> </u>		0	0	IV	
	C	 					С	С	С	
118	S	 					S	S	S	
119			<u> </u>				V	V	V	
120	Т						T	Ť	T	
121	D					1	D	D		ļ
122	F						F	F	D	
123	Y					 	† '		F	
124	Р					+		Y	Υ	
125	Α	G	S			 	P	P	Р	
126	Ĥ	Q					GS	0	1 0	
127	''	<u> </u>					0	HQ	0	
128	K				<u> </u>				The state of the s	
129	V					L	K	K	К	
130						<u> </u>	v	V	V	
	Q	R					0	RR	QR	
131	W						W		W	
132	F						F	WF	F	
133	R						R	R	<u> </u>	
134	N						N	K	R	
135	D						D	<u>IV</u>	N	
136	Q					ļ — —		D	D	
137	E						Q	Q	Q	
138	E					<u> </u>	<u>E</u>	E	Ε	•
139	Ŧ		+				E	E	E	
140		╼╤╾┼					T	T	T	
141	A G	T		$-\!\!\!\!-\!\!\!\!\!\!\perp$			TT	0	0	
142						T	G	Ğ	G	
142	V				T		V	v	<u>V</u>	
143	V			T			V	v	v	
144	S						S	S	V	
145	T						T		S	
								T	T	

Position		D	iverse A	mino A	cid		no adjuvant therapy	Chemotherapy	Immunotherapy	
146	Р						Р	Р	Р	
147	L		L				L	L	L	
148	1			1			1		1	
149	Т		1	<u> </u>			Т	T	T	
150	N				1		N	N	N	
151	Ğ	 	 			+	Ğ	G	G	
152	-		1	 	 		D	D	D	
153	W		 		 	+	W	w	w	
154	T		+		 		T	T	T	
155	F		 	<u> </u>	1	+				+
			 		ļ		F	F	F	
156	Q		ļ	-		 	Q	Q	Q	
157			ļ	ļ	ļ	<u> </u>	<u> </u>	<u> </u>	1	<u> </u>
158	L		ļ	<u> </u>	<u> </u>		L	L	L	<u> </u>
159	V			ŀ		1	V	V	V	
160	M						M	M	М	
161	L	I					L	L	L	T
162	Ē		1	1	1	1	Ē	Ē	Ē	1
163	M		1	 	t	 	M	M	M	
164	T	 	 		 -	+	T	T	T	
165	P		 	 	 	+	P	P	P	
166	Q	—	1	 	 	 				
167	Н	R		 -	 	1	Q	Q	Q	-
		R	ļ	<u>ļ. </u>	<u> </u>		0	HH	RR	ļ
168	G		ļ	ļ	ļ		G	G	G	<u> </u>
169	D				ļ	<u> </u>	О	D	D	
170	V						V	V	V	
171	Υ						Υ	Υ	Υ	
172	T						Т	T	T	
173	С					1	С	C	С	<u> </u>
174	Н		1				Н	Н	Н	
175	V		1		·		V	V	V	
176	Ē		 	<u> </u>	i -		Ē	E	Ē	
177	H		 		 -	 	H H	H	Н	
178	P		 	 	 	 	P	P	P	
179	s		 -			 	S			<u> </u>
180	L		 			ļ		S	S	
181			 		 -	 	L	L	L	ļ
182	Q		 	<u> </u>	 	ļ	Q	Q	ď	
	_ N	S	 			 	NN	0	0	
183	Р		ļ <u> </u>				Р	P	Р	
184							1	1		
185	1	T			L		11	TT	0	
186	V						V	V	V	
187	Ε						E	E	E	
188	V				l		W	w	W	
189	R					<u> </u>	R	R	R	<u> </u>
190	Α		-		l	<u> </u>	A	A	A	
191	Q		 			 	Q	Q		
192	S		 			 	s		Q	 -
193	Ē		 			 	E	S	<u> </u>	
194	S							E	E	
195				_			S	S	S	
195	A		<u> </u>				Α	Α	Α]
	<u>Q</u>		ļ				a	Q	Q	
197	_N_	S					SS	NS	0	
198	К						K	K	K	
199	М						М	М	M	
200	L						L	L	<u> </u>	<u> </u>
201	S						S	s	S	
202	G						Ğ	Ğ	G	
						 				1
203	1 1	V					0	0	()	

Position		D	iverse A	mino A	cid		no adjuvant therapy	Chemotherapy	Immunotherapy	
205	G						G	G	G	
206	F						F	F	F	
207	V						٧	V	V	
208	L						L	L	L	
209	G						G	G	G	
210	L						L	L	L	
211	i i						ı	1	1	
212	F						F	F	F	
213	L						L	L	L	
214	G						G	G	G	
215	L				I		L	L	L	
216	G						G	G	G	
217	L						L	L	L	
218	l						l	1	1	
219	l						l	ı	1	
220	Н	R					НН	0	()	
221	Н	Q					HH	0	Ö	
222	R				1		R	Ř	Ř	
223	S						S	S	S	i
224	Q	R					0	0	QR	
225	K						K	Ř	K	
226	G						G	G	G	
227	Р						Р	Р	Р	
228	Q						Q	Q	Q	
229	G						G	G	G	
230	Р						Р	Р	P	
231	Р						Р	Р	Р	
232	Р					I	Р	Р	Р	
233	Α					I	Α	Α	Α	
234	G						G	G	G	
235	L						L	L	L	†
236	L						L	Ĺ	Ĺ	
237	Н						Н	Н	Н	1

Position			Diverse	e Amino	Acid		no adjuvant therapy	Chemotherapy	Immunotherapy	
29	M						M	М	М	
_28	V						V	V	V	
_27	С						С	c	Č	
_26	<u> </u>						L	L	ĭ	
25	K	R					RR	RR	RR	
_24	F	L					ForL	ForL	ForL	
_23	Р						P	P	P	
_22	G						G	G		
21	G						G	G	G G	
_20	S			\neg		+-	S	S		
_19	C						C	C	S C	·
_18	M						M	M		
_17	Α	T				+	ĀĀ	AA	M	
_16	Α	V		+			 		AA	
_15	L	1				 -			A or V	
_14	T	+	+				<u> </u>	<u>L</u>	L	
_13	V	+					T T	T		
_12	V	+					<u> </u>	V	V	
12		+	+				T	T	T	1
	L	-					L	L —	L	
_10 _9	M	+				-	M	M	M	
9			-				L V	V	V	
8	L_	ļ	 				L	L	L L	
8	S	 					S	S	S	
_6	S	L					S	S	S	
5	Р		1				Р	Р	P	
4	L_L						L		L	
3	_ A					7	A	A	Ä	
_2	L					1		- î		
1	A	S					A or S	A or S	L	
1	G				1	 	G	G	AA	
2	_ D						D	D	G	
3	T			1		 	T -	 	D	
4	Q	R			1	 	QorR		<u>T</u>	
5	Р			1	+	 	P	Q or R	QR	
6	R		1	 	+	+	R	Р	Р	
7	F		 	 	+	 	F	R	R	
8	L		i	 	+	+		F	F	
9	E	K	W		 	+	<u> </u>	L	L	
10	Е	Q	Ÿ		 	 	1 0 1	ww	KW	
11	D	Ğ	i	P	S	 ,,-	YY	0	0	
12	К	T	 -	+-'	 	V	DS	0	DP	
13	F	Ġ	Н	R	-		K or T	K or T	K or T	
14	E	K		+~-	S	Υ	GH	0	FS	
15	c			 		 	E or K	E or K	E or K	
16	H	Q	Y	 		 	C	С	С	
17	F	<u>~</u>			 	 	0 F	YY		
18	F			 	 		F	F	() F	
19	N			 			F	F	F	
20	G						N	N	N	
21	- G +						G	G	Ğ	
22	- <u>-</u> - 						T	T	T	
23	E						E	E	E	
	R						R	R	R	
24 25	V						V	V	V	
20	Q	R					Q or R	Q or R		
26 27	F	L	Υ				FL	0	Q or R	
20	느]				L	—— V	FL	
28	D	E	Н				0	0	L	
29 30	R						R	R	0 R	
i</td <td>С</td> <td>G</td> <td>Н</td> <td>L</td> <td>R</td> <td>Y</td> <td>0</td> <td></td> <td>ĸ</td> <td></td>	С	G	Н	L	R	Y	0		ĸ	

Position		Di	verse A	mino A	oid		no adjuvant therapy	Chemotherapy	Immunotherapy	
31	F		V	l			Forl	Forl	FI	
32	Н	Y					HH	0	0	
33	Н	N	1				0	0	HH	
34	Q						Q	Q	Q	
35	Ε		i				E	E	Ε	
36	Е						E	E	Ē	
37	F	L	N	S	Y		0	LY	NS	
38	Α	L	V				Ö	0	W	
39	R			·			Ř	Ř	R	
40	F	Y			 		ForY	ForY	FF	
41	D						D	D	D	
42	S						s	S	S	
43	D			 	 		D	D	D	
44	v			l	-		V	V	v	
45	Ğ				 		Ğ	G	G	
46	E		 		 		E	E	Ē	
47	F	Y	 -	ļ	 		For Y	ForY	For Y	
48		<u> </u>			 					
	R						R	R	R	
49	A	ļ		ļ	ļ		A	Α	A	
50	<u>v</u>	<u> </u>			-		V	V	V	
51	T						T	Ţ	Ţ	
52	E	L		ļ			E	E	E	
53	L						L	L	L	
54	G						G	G	G	
55	R						R	R	R	
56	Р						Р	Р	Р	
57	Α	D	S	V	ll		AV	AV	·AV	
58	Α	E					A or E	A or E	A or E	
59	E						E	E	E	
60	Н	S	Υ				0	YY	HS	
61	W						W	W	W	
62	Z						N	N	N	
63	S						S	S	S	
64	Q						Q	Q	Q	
65	K						K	K	K	
66	D						D	D	D	
67	F		L	· · · · · ·			FF	FI	FL	
68	L						L	L	L	
69	Ε						E	E	E	
70	D	Q	R				0	DD	0	
71	Ā	Ē	K	R			Ä	A	Ä	
72	R						R	R	Ř	
73	Α	G					ĀĀ	A or G	A or G	
74	A	E	L	Q	R		0	LL	AE	<u> </u>
75	V						V	V	V	
76	Ď						D	D	D	
77	N	Т					N or T	N or T	N or T	
78	V	Ÿ			 		W	VorY	VY	
79	ċ	<u> </u>					C	C	C	
80	R					_	R	R	R	
81	H						H	H	H	
82	N						N	N N	NI NI	
83	Ÿ						Y	Y	N	
84	Ġ									
85	A	v					G	G	G	
86	Ğ	V					A or V	A or V	vv	
87	E	<u> </u>					W	GV	GG	
88	S						E	E	E	
89	F						S	s	S	
09							F	F	ĪF	l

Position	Diverse Amino Acid				cid	no adjuvant therapy	Chemotherapy	Immunotherapy	
90	T					T	Т	T	
91	V					V	V	V	
92	Q					Q	Q	Q	
93	R					R	R	R	
94	R					R	R	R	
95	V					V	V	V	
96	E	Н	Q	Y		EQ	0	0	
97	Р					Р	Р	P	
98	Е	Κ				EK	E or K	EK	
99	V					V	V	V	
100	T					T	T	T	
101	V			 	 	V	V	V	
102	Ŷ				 	Ý	Ÿ	Ý	
103	P				 	P	P	P	
104	A	S		 	 	ĀĀ	A or S	AK	0
105	- 2	3	<u> </u>						
	K				 	K	K	K	ļ
106	T		<u> </u>		ļ	T	Ţ	T	<u> </u>
107	Q					Q	a	Q	
108	Р				ļ	Р	Р	Р	
109	L_L					L	L	L	
110	Q			<u> </u>	ļ	Q	Q	Q	
111	Н					Н	Н	Н	
112	Н		l			Н	Н	Н	
113	N		<u> </u>		1	N	N	N	
114	L					L	L	L	
115	L					L	L	L	
116	>					V	V	V	
117	С					С	С	С	<u> </u>
118	S					S	S	S	
119	V					V	V	V	
120	N	S		<u> </u>		S or N	NN	SS	
121	F					F	F	F	
122	G			_		G	Ġ	Ğ	
123	Υ					Y	Y	Ÿ	
124	Р					P	P	P	
125	G					Ġ	Ğ	G	
126	s					s	Š	s	· · · · · · · · · · · · · · · · · · ·
127	Ť				 	+ + +	<u> </u>	<u></u>	
128	E					Ė		<u> </u>	
129	v					 	E		
130	Ř						V		
131	w				 	R	R	R	
132	F					W	W	W	
133		-				F	F	F	
134	_ L N	R				RR	L or R	RR	
					 	N	N	N	
135	<u> </u>				<u> </u>	G	G	G	
136	Q					Q	Q	Q	
137	_ E					Ε	E	E	
138	E					E	E	E	•
139	K					K	K	K	
140	_ <u>A</u>	T				0	II	0	
141	G					G	G	Ğ	
142	M	V				W	M or V	W	
143	V	I				V	V	V	
144	S	T				S	S	S	
145	T					T	T	T	
146	G					G	Ġ	Ġ	
147	L					 [L	L	
148						1			

Position		Ċ	Diverse	Amino /	Acid		no adjuvant therapy	Chemotherapy	Immunotherapy	
149	Н	Q				Т	H or Q	НН	НН	
150	N	 	+				N N	N	N	
151	G			-			G	G	G	
152	D	 	 				D	D	D	
153	W	1	 	+		 	T W	W	- W	-
154	T	<u> </u>	+	+	+		T	T	T	
155	F	+	 	+	 	 	F	F	F	-
156	Q	 	·		 	+	i a	Q		
157	Ť		+	+	 		 	T	T	
158	L		 	+			 	 		
159	V			+		+	 	V	L	
160	М	 	+	+	+	_	M	M		-}
161	L	+	+	+	+				M	
162	E	 	+	 			<u> </u>	L	<u> </u>	ļ
163	+ -				+	_	E	E	E	
164	F	— , ,	+	+			T	T	T	1
		V	-	-			0	0	0	
165	Р	 	ļ				Р	P	Р	
166	Q	R	ļ			<u> </u>	Q or R	Q or R	RR	
167	S	 	 				S	S	S	
168	G			<u> </u>	<u> </u>		G	G	G	
169	E	ļ					E	E	E	
170	V						V	V	V	
171	Υ		<u> </u>				Υ	Υ	Y	
172	T	<u> </u>					T	T	T	
173	С						С	С	С	
174	Q						Q	Q	Q	
175	V						V	v	v	
176	E					T	E	Ē	Ē	
177	Н						Н	Н	H	
178	P					1	Р	Р	P	
179	S				1		S	S	S	
180	L	V		1		1	LorV	L or V	L or V	
181	М	T					0	0		
182	S					-	Š	S	0	
183	Р					 	P	P	S P	
184	L				<u> </u>	 	† <u> </u>	L		
185	T					 	Ť	<u> </u>	<u>†</u>	
186	V						i v	v		
187	Е			<u> </u>		 	E	E	V	
188	W					+	w	w	E	
189	R	Ş			 	 	RR	Rors	W	
190	Α			<u> </u>		 	A		R or S	
191	R				 	 	R	A R	A	
192	S			 	-	 			R	
193	Ē			 	 	 	S	S	S	
194	S			 	 	 	E	E	E	
195	Ā			 	 	 	S	S	S	
196	â				ļ — —	 	A	A	Α	
197	S			<u> </u>	L		Q	Q	Q	
198	K						S	S	S	
199	M			ļ			К	K	K	
200	L					 	M	М	M	
201	S					├	L	L	L	
	G					├	S	S	S	
202 1							G	G	G	
202							V	V		
203	V						<u>v</u>		V	
203 204	V G						G	G	G	
203 204 205	V G G						G G	G G	G G	
203 204	V G						G	G	G	

Position		Di	verse Am	ino Acid		no adjuvant therapy	Chemotherapy	Immunotherapy	
208	L					L	L	L	
209	G					O	G	G	
210	١				1	L	L	L	
211	١					L	با	L	
212	F					F	F	F	
213	L					L	L	L	
214	G					G	G	G	
215	Α					A	Α	Α	
216	G					G	G	G	<u> </u>
217	L				1	L	Ļ	L,	
218	F					F	F	F	
219	1					l I		1	
220	Υ					Υ	Υ	Y	
221	F					F	F	F	
222	R					R	R	R	
223	N					N	N	N	
224	Q					Q	Q	Q	
225	K					К	K	K	
226	G					G	G	G	
227	Н					Н	H	H	
228	Ş					S	S	S	
229	G					G	G	G	
230	L					L	L	L	
231	P	Q				P or Q	P or Q	QQ	
232	Р					Р	Р	Р	
233	R	Т				RorT	R or T	R or T	
234	G					G	G	G	
235	F					F	F	F	
236	L				<u> </u>	L	L	L	
237	_s_					S	S	S	

Position		Di	verse A	mino Acid		Amino Acid Configuration to Inhibit Metastases
_29	М	<u> </u>				M
28	М					M
_27	V					V
_26	Ĺ					L
25	Q					Q
_24	v	-				V
23	Š					S
22	Ā		-			A
21	A			-		A
_20	P					P
_19	R					R
_18	Ť					T
_17	v					V
16	Ā					Ā
_15	Ĺ					<u> </u>
_14	T					T
						Ä
_13	Α					- î
	L		ļ			
11	L	ļ	 			L NA
_10	M		 			M
9	V					V
8	Ļ.					L
	Ļ					
_6	Ť					Ţ
_5	S			<u> </u>		S
4	V					V
_3	V					V
_2	Q					Q
111	G					G
11	R					R
2	Α					A
3	T					T
4	P					Р
5	E					E
6	N					N
7	Υ					Υ
8	L L	V				0
9	F	Н	Υ			0
10	Q					Q
11	G	L				0
12	R		 			R
13	α.		ļ			Q
14	E					E
15	С					C
16	Υ					Y
17	Α					A
18	F					F
19	N					N N
20	G					G
21	T					T
22	Q					Q
23	R					R
24	F		T			F
25	L					L
26	E					E
27	R					R
28	Υ					Y
29						
30	Y					Y

Position	I	Di	verse A	mino Acid	Amino Acid Configuration to Inhibit Metastases
31	N		- 	1	· N
32	R				R
33	Ε				E
34	E			· · · · · ·	E
35	F	L	Y		0
36	Α	V			0
37	A R				R
38	F				F
39	D				D
40	S				S
41	D				D
42	V				V
43	G				G
44	E				E
45	F				F
46	R				R
47	Α				Α
48	V		_		V
49	Ť				T
50	E				Ę.
51	L				L
52	G				G
53	R				R
54	Р				Р
55	Α	D	E		AA
56	Α	Е			0
57	D	E			0
58	Υ				Υ
59	W				W
60	N	Ĺ			N
61	S				S
62	Q				Q
, 63	Κ				K
64	D				D
65	F		L		0
66	L				L
67	E			ļ	<u> </u>
68	E				E
69	E	K			0
70	R				R
71	A			 -	A
72	٧			 	V
73	Р			 	P
74	D				D
75	R	<u> </u>			R
76	1	М	V		0
77	O C				C
78	R				R
79	_ H		ļ	 	Н
80	N				N.
81	Υ			 	Y
82	E				E
83	L			 	<u>L</u>
84	ח	G			0
85	E	G			0
86 87	A	P V			0
88	M T	V			0
89					T
	L				L

Position		Di	iverse A	mino A	cid		Amino Acid Configuration to Inhibit Metastases
90	Q		1		T		Q
91	R	-	<u> </u>	-	 	 -	R
92	R		 	 	 	+	R
93	V		 	-	1	 -	<u>V</u>
					 	+	Q
94	Q				 	 	
95	Р		L		ļ <u> </u>		Р
96	K	R		<u> </u>	<u></u>	1	0
97	V						V
98	N					T	N N
99	V						V
100	S		 		1	 	S
101	P			_		 	P
102	s		-		 	+	S
	- 3				ļ		K
103	K				ֈ	+	<u> </u>
104	K				L		K
105	G			l	<u> </u>	1	G
106	Р				1		Р
107	L				T		L
108	Q		† — —		1	 	Q
109	H				 	 -	Ĥ
110	Н	ļ	\vdash	 	 	 	H
	NI NI		 	 	 	+	
111	N	ļ	<u> </u>		 	+-+	N
112	L		<u> </u>		<u> </u>	<u> </u>	<u> </u>
113	L				<u> </u>	<u> </u>	L
114	V				Ī		V
115	С						C
116	Н		<u> </u>		1		Н
117	V		 		†	1	V
118	Ť		h		 	+	T
119	Ď		 		 	+ - +	D
119	F	-	-		 	 	
120				ļ	<u> </u>	 	F
121	Υ		ļ		ļ		Υ
122	Р			<u> </u>	<u> </u>	<u> </u>	P
123	G				1		G
124	S						S
125	I						
126	a				1		Q
127	V			 			V
128	R			·		+	R
129			 		 	 -	
129	8		 	<u> </u>	 	 -	W
130	F					 	F
131	L		ļ		ļ	<u> </u>	L L
132	N						N
133	G						G
134	Q						Q
135	E				i	1	Ē
136	E		l		 	 -	<u> </u>
137	T		 			 -	
138	A		 		 	 	T
	^					+	A
139	G		ļ <u> </u>			\vdash	G
140	V						V
141	V		L				V
142	S						S
143	T					T	T
144	N					 	N
145	Ĺ				 		L
146	ī				 	 	
147	R				-		
148	N				 	 -	R .
140	<u>IN</u>				L	L	N

Position	Γ	Di	verse An	nino Acid		Amino Acid Configuration to Inhibit Metastases
149	G			T	T	G
150	D					D
151	w					W
152	T		 			Т
153	F		ļ · · · · · · · · ·			F
154	Q		 -			Q
155	ī		 -			i
156	- 		 			Ĺ
157	V					V
158	M					M
159	L					L
160	E		 			E
160	M		-			M
161	- IVI					T
162	T					P
163	P		 			
164	Q					Q
165	Q					Q
166	G		 			G
167	D					D
168	V					V
169	Υ					Y
170		T				0
171	С					C
172	Q					Q
173	V					V
174	Ε					E
175	Н		·			Н
176	T					T
177	S					S
178	L	М				0
179	D					D
180	S			i		S
181	Р					Р
182	V					V
183	T					Т
184	V					V
185	E					E .
186	W			· · · · · · · · · · · · · · · · · · ·		W
187	K					K
188	Α			· · · · · · · · · · · · · · · · · · ·		A
189	Q					Q
190	S					S
191	D					D
192	S				+	S
193	Ā				1	A
194	R		 		+	R
195	S		 	- 	 	S
196	K				+	K
197	T				1	T T
198	-		 		+	L'
199	Ť					T
200	Ġ		 		+	G
201	A		 		+	A
202	Ĝ				+	
203	G				+	G
203	F				 	G
205	V					F
206	L		-			V
207	G				+	L L
201	٦					G

Position		Diverse Amino Acid	Amino Acid Configuration to Inhibit Metastases
208	L		L
209	ı		
210	ı		
211	С		C
212	G		G
213	V		V
214	G		G
215	1		
216	F		F
217	М		M
218	Н		Н
219	R		R
220	R		R
221	S		S
222	К		K
223	К		K
224	V		V .
225	Q		Q
226	R		R
227	G		G
228	S		S
229	Α		A

Position	· · · · ·	Di	verse A	mino A	cid	Amino Acid Configuration to Inhibit Metastases
_32	М	<u></u>	1	1	1	M
_31	S					S
_30	W					W
_29	К					K
_28	К		i			K
_27	Α	S				0
26	L					Ĺ
_25	R		-		1	R
_24	T	· · · · · ·				
_23	Р					Р
_22	G				1	G
_21	D	G				0
_20	L					L
_19	R					R
_18	A	V			<u> </u>	0
_17	Α				1	Ă
_16	T	i				T
_15	V		1		1	V
14	Ť				1	Ť
_13	Ĺ			—	1	Ė.
_12	М				†	M ·
_11	L					L
_10	Α	S				0
_9		М			<u> </u>	Ŏ
8	L				 	Ľ
8 7	S				†	S
6	S	Т			1	0
6 5	Ĺ	P	s	†	†	Ů Ú
4	Ĺ	V			 	O O
4	A				1	A A
_2	E				 	E
_1	G		i	<u> </u>		G
1	R					R
2	D				1	D
3	Р	S			1	0
4	Р				 	P
5	E					E
6	D				 	D
7	F				1	F
8	V					V
9	F	L	Y	<u> </u>	†	0
10	a		·		1	ă
11	F					F
12	K	-		i –		K
13	A	G			†	0
14	L	M		<u> </u>	t	LM
15	0				1	C
16	- Y				 	Y
17	F				† —	F
18	T			·	<u> </u>	T
19	N				†	i N
20	G					G
21	T					T
22	Ē					E
23	ī	R		_	 	0
24	v					V
25	R				<u> </u>	R
26	G	L	Υ	-	<u> </u>	0
27	v				 	V

28	Position	Γ	Di	verse A	mino A	cid	Amino Acid Configuration to Inhibit Metastases
29	28	s		1	1	T T	
30			<u>-</u>			 	
31		Н	S	Y			0
32						 	
33							
34	33	N				 	
35			l				
36	35					 	F
37							
38	37	<u> </u>		V		 	
39				·	 	 	0
40	30	B		· · · · · · ·		 	R
41 D S S S S S S S S S S S S S S S S S S						 	F
42 S 43 D 44 V 45 E 6 E V O 47 F Y O 48 R 49 A 50 V 51 T 52 L F P 53 L Q O 54 G 55 L F P 0 O 54 G 55 L P 0 O 55 L P 0 O 57 A D 59 E 60 Y 61 W 62 N 63 S 64 Q 65 K 66 D 67<						 	<u> </u>
43		<u> </u>				 	
44 V 45 E G 46 E V 47 F Y 48 R R 49 A A 50 V V 51 T T 52 L P O 53 L Q G 54 G G G 55 L P R O 56 L P R O 57 A D S V O 58 A A A A A 59 E B					 	 	5
45 E G O O O O O O O O O O O O O O O O O O					 	 	
46 E V 0 47 F Y 0 48 R R A 49 A A A 50 V V V 51 T T T 52 L P O O 54 G G G G 55 L P R O O 56 L P D O O O 56 L P D O		<u>-</u>	 	ļ		 	<u>v</u>
47 F Y		 				 	
48		트	<u>V</u>				0
49 A 50 V 51 T 52 L 53 L 54 G 55 L P 56 L P 57 A D S 59 E E 60 Y Y Y 61 W W W 62 N N N 63 S S S 64 Q Q Q 65 K K K 66 D E Q 67 I V Q 68 L L Q 69 E G R 70 E G R 71 A D K T 72 R R R 73 A A A 74 A E S Q 66 D D			Ψ_	-	 	1	
SO	48	K.					<u> </u>
51 T T T T S2 L P O		A	ļ		ļ	ļ	
S2	50					 	
53 L Q 0 G G G S S G G S L P R D O O D						ļ	
54 G D G G G A G G A G G G A G G A G G A G G G A G G G A G							
S5	53		Q			↓	
S6	54			<u> </u>			
57 A D S V O O A	55			R		L	0
58 A 59 E 60 Y 61 W 62 N 63 S 64 Q 65 K 66 D E 67 I V 68 L 69 E E 70 E G R 71 A D K T 72 R R O O 73 A A A A 74 A E S O O 75 L V O D D 77 R T T R RT 78 V V V V 79 C C C R 80 R R R R 81 H H H H 82 N N N N 84 E </td <td>56</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0</td>	56						0
S9 E	57	_ A	D	S	V	ļ	
60 Y	58	_ A					
61 W		E					
62 N S S S S S S S S S S S S S S S S S S						 	Y
63 S S S S S S S S S S S S S S S S S S S						ļ	<u>W</u>
64 Q Q			ļ			<u> </u>	<u>N</u>
65 K		<u> </u>					S
66 D E O O O O O O O O O O O O O O O O O O							Q
67					L		K
68 L L L E E E E E E E E E E E E E E E E					<u> </u>		0
69 E G R 0						L	0
70 E G R () 71 A D K T () 72 R R 73 A S S S S S S S S S S S S S S S S S S							L
71 A D K T		E					
72 R R A A A A A A A A A A A A A A A A A							0
73 A E S () 74 A E S () 75 L V () 76 D D D 77 R T RT 78 V V V 79 C C 80 R R R 81 H H H H H H H H 82 N N N N N N N N N N N N N N N N N N N		Α	D	K	Т		
74 A E S () 75 L V () 76 D D D 77 R T RT 78 V V V 79 C C 80 R R 81 H H H H H H H 82 N N N N N 83 Y V V 84 E Q () 85 L V ()							
74 A E S () 75 L V () 76 D D D 77 R T RT 78 V V V 79 C C 80 R R R 81 H H R R 82 N N N N N N N N N N N N N N N N N N N	73	Α					A
75 L V	74	Α	E	S			0
77 R T V V V V V V V V V V V V V V V V V V	75		V				0
78	76					L	
78	77	R	T				RT
79 C C R R R R R R R R R R R R R R R R R	78	V					V
80 R R R R R R R R R R R R R R R R R R R		С					С
81 H H N N N N N N N N N N N N N N N N N	80	R					R
82 N N N N Y S N Y S N N S N N S N N N N N	81	Ι					Н
83 Y Y Y 84 E Q 0 0 0 0 0	82						N
84 E Q 0 0 0							Y
85 L V 0	84	E	Q				
86 A E G 0	85						Ŏ
	86	Α	_ E	G			Ŏ

Position	Γ	Di	verse A	mino Acid	.	Amino Acid Configuration to Inhibit Metastases
87	F	L	Y	1		LL
88	R	├ -				R
89	Ĝ	T				0
90	Ť	Ť				0_
91	 	- '				L
92	à					Q
93	R					R
94	R					R
95	V					V
			ļ. -			E
96	E					
97	Р					Р
98	T		L	ļļ		T
99	V					V
100	T					T
101	ı					l l
102	S					S
103	P					P
104	S					S
105	R				1	R
106	T	i				Т
107	E					E
108	Ā					Ā
109	L		-			Ĺ
110	N					N
111	Н	 				Н
112	H					H
113	N	 				N
		 				
114	ļ Ļ					L
115	Ļ	V				L N/
116	1					IV
117	C	ļ				C
118	S	L				S
119	V	ļ				V
120	T					T
121	D	<u> </u>				D
122	F					F
123	Υ					Y
124	Р	L				P
125	Α	G	S			AA
126	Н	a				0
127						i i
128	К					К
129	V					V
130	Q	R				0
131	W		i			W
132	F					F
133	R					R
134	N					N N
135	Ö					
136	Q			-		D Q
137	E			- +-		
138	E					E
	T					E
139		-			- +	T
140	A	Т				0
141	G			_		G
142	V		L			V
143	V .					V
144	_ S					S
145	T	L				T

146 P	Position			Diverse	Amino	Acid		Amino Acid Configuration to Inhibit Metastases
147	146		T		1	T		Admino Acid Configuration to innibit Metastases
148	147			T	_	\dashv	+	
149	148					_		
150								
151 G			 					
152	151	G						
153 W	152	D		+		 -		
154	153	1 1/4	+					
155	154							
156	155	╅╌╧╌	┥—					
157	156							
158			+-					Q
159	150		-					
160					4			L
160	159							V
161	160						T	M
162 E	161							
164	162		\perp				\neg	
164	163	M						
165 P P P P P P P P P P P P P P P P P P P	164	T						
166	165	P						
167 H R O O O O O O O O O O O O O O O O O O	166				\top			
168 G	167	Н	R		1			
169				 	-			- 0
170 V	169		 					
1711 Y Y 172 T T T T T T T T T T T T T T T T T T T			1		+			
172 T T T T T T T T T T T T T T T T T T T	171		 	+	+			
173			 					
174 H H H H H H H H H H H H H H H H H H H	173		 		+		-	
175	174	H	1	+	+	+		C
176 E	175	17	+	+				
177 H H H H H H H H H H H H H H H H H H	176	-	 		-			
178	177		 	+	+			E
179	170		 					Н
180	170	-	 		 			P
181 Q				 		<u> </u>		
182	180				<u> </u>			
183 P	181			 	ــــــ			
184			s	<u> </u>				
185								
186					<u></u>			
187 E	185		T		\perp			
Table Family Fa	186							
No		E					1	
190 R		W					T-	
190 A A A A A A A A A A A A A A A A A A A	189	R				1	 	
191 Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q	190	Α				1	†	
192 S S S S S S S S S S S S S S S S S S S	191	Q				1	1	
193 E		S					1	
194 S S S S S S S S S S S S S S S S S S S	193	Ε			i —	 	+	
195 A	194	S				 	+	
196 Q A 197 N S Q 198 K 199 M K 200 L 201 S S 202 G S 203 I V 204 G						 	 	
197 N S Q 198 K O O O O O O O O O O O O O O O O O O	196					 	 	A
198 K			S			 	 	
199 M K 200 L 201 S 202 G 203 I V 204 G	198					 -		0
200 L M 201 S L 202 G S 203 I V G						 	 	
201 S L 202 G S 203 I V G	200						 	
202 G S S G S G II	201					 		L
203 I V G II	202							S
204 G			-, 					G
G			- <u>v</u>					
		9						G

109 / 129

Diagram 109

) I

Position			Diverse Amino Acid	Amino Acid Configuration to Inhibit Metastases
205	G			G
206	F			F
207	V			V
208	Ĺ			
209	G			G
210	L			L
211				
212	F			F
213	L			L
214	G			G
215	L			L
216	G			G
217	L			L
218	T			1
219	T			
220	Н	R		0
221	Н	Q		0
222	R			R
223	S	1		\$
224	Q	R		QR
225	K			K
226	G			G
227	Р			P
228	Q			Q
229	G			G
230	P			P
231	Р			P
232	Р			P
233	A			
234	G			A G
235	L			
236	L			<u> </u>
237	Н			L H

Position	r	Di	verse A	mino A	rid		Amino Acid Configuration to Inhibit Metastases
_29	М	 	10,36 /	1	Ĭ	T	M
_28	V	 		 	 	 	V
_27	ċ	 	 		 	 	С
_26	Ľ				-	t	L
25	K	R				 	0
24	F	L	 			 	ĽĹ
_23	P	-			 	 	Ρ
22	G			-	 	 	G
_21	G					 	G
_20	s	 	 			 	S
_19	c					 	C
_18	М				 		M
_17	A	Т	 	 	 	 	0
16	A	l v		ļ		 	0
_15	L		 	 	 	-	L
13	T	 					т т
13	V		 		 	 	· v
_12	T	 			 	 	T
_12		 			 		<u> </u>
11	M		 			 	M M
_10	V		 	 	 	 	V
-3	L	 			 	 	L
_8 _8	S	 				 	S
6	S	-			 	 	S
5	P	 				 	P
-3					 	 	· · · · · · · · · · · · · · · · · · ·
4	L				-	 	L A
3	A L	 	 		 	 	
_1	A	S	 		 	 	<u>L</u>
1	G	-3-			 	 	G
2	D	-			 	 	D
3	-					 	T .
4	à	R		 	 	 	0
5	P	- K		 	 	 	P
6	R	 	 	 		 	R
7	F	 	 	 	 	 	F
8	Ŀ	 			 	 	
9	E	К	w		 	 	0
10	E	à	Y			-	0
11	D	Ğ	- :	Р	s	V	0
12	K	T			-	 	0
13	F	Ġ	Н	R	S	Y	0
14	E	K	 - 	 -:`	-	 - 	0
15	č	 '``	 	 		 	C
16	Н	Q	Υ	 	 	 	0
17	F		 -			 	F
18	F	 			 	 	F
19	N		 		 		N N
20	G	 			 	t	G
21	T		 		 	 	T
22	Ė						E
23	R	 	-			 	R
24	V	<u> </u>	 		 	 	V
25	Q	R			 	 	0
26	F	L	Y		 		0
27	Ĺ		- '		 	-	
28	D	E	Н			 	<u>L</u>
29	R			-		 	0
30	C	G	Н	L	R	Y	R
							0

Position	Т		Diverse	Amino	Acid	Aming Acid Confirmation 4 Living
31	F	1	V	<u> </u>	T	Amino Acid Configuration to Inhibit Metastases
32	H	+ 🙀	 	+		0
33	H	N	+		+	0
34	Q	N				0
35				+		Q
35	E					E
36	E					E
37	F	L_	N	S	Υ	0
38	Α	L	V			Ö
39	R					R
40	F	Y				0
41	D					V
42	S		 	_		
43	D	1	1	 	+	S
44	V		+	+	 	D
45					-	V
45	G		-	 		G
46	E	ļ <u></u>				E
47	F	Y				0
48	R					Ř
49	Α					A
50	V		1		1 -	v
51	T			1	+ -	
52	E		 	 	+	T
53	L	 	 		+	E
54	G	 	 	 	+	L L
55	R	 		├ ──		G
56	 ^	 -				R
55	Р			<u> </u>		Р
57	Α	D	S	V		0
58	Α	E				0
59	E					E
60	Н	S	Y			0
61	W					
62	N				 	W
63	S				_	N
64	Q				 	S
65	ĸ				 	Q
66	D				-	K
67	F	-			<u> </u>	D
			L		ļ <u>.</u>	0
68						L.
69	E					E
70	D	ρ	R			0
71	Α	Ε	K	R		0
72	R					R
73	Α	G				0
74	Α	E	L	Q	R	
75	V				<u> </u>	0
76	D					V
77	N	-				D
78	V	T				0
79	č					0
80	R					C
81						R
82	H					H
6/	N					N
	v 1					Y
83	Υ					G
83 84	G					
83 84 85	G A	V				
83 84 85 86	G A G	V				0
83 84 85	G A G					0
83 84 85 86 87	G A G E					0 0 E
83 84 85 86	G A G					0

Position	1		Diverse	Amino	Acid		Amino Acid Configuration to Inhibit Metastases
90	T			1	Ţ -		T
91	V			\top			V
92	Q						Q
93	R						R R
94	R					+-	R
95	V			+	+		
96	E	Н	a	Y			V
97	P		+-	 '			0
98	E	K		+			P
99	V	 ``	+	+-			0
100	T			+-	 		V
101	T v	+		+			T T
102	Ť			+			V
103		+					Y
	Р						P
104	Α	S	_				0
105	K						K
106	Т						Ť
107	Q						Q
108	Р			1	\top		P
109	L			 			
110	Q		1	 	 		L
111	H	1		 	+		Q
112	Н	_	+	┼	-	-	Н
113	N	+		┨──			Н
114	1 :	+	+				NN
115	+ :		-				
116				 	+		L. L.
	V			<u> </u>			V
117	C						C
118	S			Ĺ			S
119	V	ļ.,					V
120	N	S					0
121	F						F
122	G						G
123	Y			L			Y
124	P						P
125	G						G
126	S						S
127							
128	E						
129	V				 		E
130	R					+	<u>v</u>
131	W				 	+	R
132	F				 	+	W
133	L	R			 	1 - 1	F
134	N				 	+-+	0
135	G				 	+	N N
136	ď				 -		G
137	_E				<u> </u>	 	Q
138	E				 		E
139	ĸ						E
140	A	T					К
141	Ĝ						0
141	<u> </u>	 _				\Box	G
142	M	V					0
143	V						V
144	s						S
145	Т						
146	G	T					
147	L					 	G
148							L

Position			Diverse A	mino Ad	cid	Amino Acid Configuration to Inhibit Metastases
149	H	Q				()
150	N					N
151	G					G
152	D					D
153	W					W
154	T					T
155	F					F
156	Q					Q
157	T					T
158	L					L
159	V					V
160	М					
161	L	1				M
162	E	1	1			L
163	 	+	+			E
164	F	1 V	+			T
165	P	+ -	+			0
166	d	R	+			Р
167	S	+ ~	+			0
168		+	+			S
169	G	+	+			G
170	† 5	+	+			E
171						V
171	Y	+	├ ─			Υ Υ
	T	-				
173	C					C
174	Q					Q
175	V	ļ				V
176	E					E
177	Н					Н
178	Р					P
179	S					S
180	L	V				0
181	M	T				0
182	S	<u> </u>				S
183	Р					P
184	L					
185	T	<u> </u>				T
186	V					V
187	E	L				E
188	W					W W
189	R	S				
190	Α					0 A
191	R					
192	S					R
193	E					Ŝ
194	S					E
195	Α			$\neg +$		S
196	Q				-+-	A
197	S					Q
198	K					S
199	М				-+-	K
200	L					M
201	s			-+		L
202	Ğ		+-			\$
203	V				-+-	G
204	Ġ					V
205	Ğ					G
206	F	+				G
207	v					F
	_ 			L		V

Position		Di	verse Amino Acid	Amino Acid Configuration to Inhibit Metastases
208	L			L
209	G			G
210	L			L
211	L			L
212	F			F
213	L			L L
214	G			G
215	Α			Α
216	G			G
217	L			
218	F			F
219				
220	Y			Y
221	F			F
222	R			R
223	N			N
224	Q			Q
225	К			K
226	G			G
227	Н			Н
228	S			S
229	G			G
230	L			L
231	Р	Q		0
232	Р			P
233	R	Т		0
234	G			Ğ
235	F	1		F
236	L			L
237	S	Ĭ		S

Position		Di	verse A	mino A	cid	Amino Acid Configuration With Less Tendency to Malignancy
_29	М					M
_28	М					M
_27	٧					V
_26	٦					
_25	Q					Q
_24	V					V
_23	S					S
22	Α			 		A
_21	A					A
_20	P			†	 	Р
_19	R			 		R
_18	T			 	 	T
_17	l ·			 	 -	T V
						
_16	Α			L	ļ	A
15	L				ļ	L
_14	Т				L	T
_13	Α			<u> </u>	<u></u>	Α
_12	L			<u> </u>		L.
11	L			<u></u>		L
_10	M			1		M
_9	V					V
8	L					L
7	L					L
6	T					T
_6 _5	S			†	 	S
	V					v
4	v		 	 	 	V
2	à		 		 	Q
1	G		 		 	T G
1	R			 	 	
2					├	R
3	A T					A
3				-		T
4	Р				 	Р
5	E					E
6	N					N
7	Υ				<u> </u>	Υ
8	L	>				LL LL
9	F	H	Υ	<u> </u>	<u> </u>	0
10	Q				<u> </u>	Q
11	G	L	<u> </u>			<u> LL</u>
12	R				<u> </u>	R
13	Q			i		Q
14	E					E
15	С		1		T	C
16	Υ				1	Y
17	Α		Ī		1	Ä
18	F			1		F
19	N				 	N
20	G				l	G
21	T				 	T T
22	Q	·		1	 	Q
23	R		<u> </u>		 	<u> </u>
24	F			 		R
25						F
<u>∠</u> 2	L		_		ļ	L
26	E			<u> </u>	ļ	E
	R			<u> </u>		R
27	- <u>, </u>					
28	Υ			 		Y
28 29 30	Y I Y					I Y

Signature Sign	Position		Di	verse A	mino Acid	i	Amino Acid Configuration With Less Tendency to Malignancy
32	31	N					N
Say E	32						
Section Sect	33						
SS	34	E					
38	35	F	L	Y			0
ST							0
38	37	R					R
39	38	F					
40	39	D					
A1		S					S
42	41	D					D
43 G							V
### ### ### ### ### ### ### ### ### ##							G
## ## ## ## ## ## ## ## ## ## ## ## ##					-		
A66					1		
47	46				 		
48					 -		
49					 		
SO					+-+	——————————————————————————————————————	
51 L 52 G 53 R 54 P 55 A 56 A 57 D 58 Y 59 W 60 N 61 S 62 Q 63 K 64 D 65 F 1 L 66 L 67 E 68 E 69 E 69 E 69 E 67 E 68 E 69 E 70 R 71 A 72 V 73 P 74 D 75 R 76 I M V 78 R 79 H			 		 		
S2 G			 		 		
S3					 		
54 P F 55 A D E 56 A E O 57 D E EE 58 Y Y Y 59 W W W 60 N N N 61 S S S 62 Q Q Q 63 K K K 64 D D D 65 F I L O 66 L L L L 67 E E E E 69 E K O O O 70 R R R R R 71 A A A A Y 72 V V V T D D D D D T R R				-			
S5					 -		<u> </u>
S6				-	 		
S7					++		
58 Y S W W W W W W S S N				ļ	 -		
S9					 -		
60 N S S S S S S S S S S S S S S S S S S							ļ
61 S			-	 	├ -		
62 Q				 			
63 K D D D D D D D D D D D D D D D D D D			 	<u> </u>	 -		
64					 		
65 F I L					 		
66 L			<u> </u>	 			
Fraction Fraction							
68 E K () 70 R R R 71 A A A 72 V V V 73 P P P 74 D D D D 75 R R R R R 76 I M V III III <t< td=""><td></td><td></td><td>ļ</td><td></td><td></td><td></td><td></td></t<>			ļ				
69 E K					 -		<u> </u>
70 R 71 A 72 V 73 P 74 D 75 R 76 I 77 C 78 R 79 H 80 N 81 Y 82 E 83 L 84 D 84 D 85 E 86 A 87 M W W MM W MM W MM W			ļ.,,		ļl-		
71 A A 72 V 73 P P 74 D D 75 R R 76 I M V 77 C C 78 R R 79 H H H 80 N N N 81 Y Y Y 82 E E E 83 L L L 84 D G GG 85 E G GG 86 A P MM 87 M V MM 88 T T T			<u>K</u>				
72 V 73 P 74 D 75 R 76 I 77 C 78 R 79 H 80 N 81 Y 82 E 83 L 84 D 85 E 86 A 87 M 88 T							
73 P P 74 D D 75 R R 76 I M V 77 C C 78 R R 79 H H H 80 N N N 81 Y Y Y 82 E E E 83 L L L 84 D G G 85 E G G 86 A P MM 87 M V MM 88 T T T	/1						
74 D D 75 R R 76 I M V 77 C C 78 R R 79 H H H 80 N N N 81 Y Y Y 82 E E E 83 L L L 84 D G GG 85 E G GG 86 A P MM 87 M V MM 88 T T T			<u> </u>				
75 R R R R R R R R R R R R R R R R R R R			 		 		
76 I M V II 77 C C C 78 R R R 79 H H H 80 N N N 81 Y Y Y 82 E E E 83 L L L 84 D G GG 85 E G GG 86 A P MM 87 M V MM 88 T T T			 	ļ			
77 C C R R R R R R R R R R R R R R R R R	75		 		 		
78 R 79 H 80 N 81 Y 82 E 83 L 84 D G 85 E G 86 A P 87 M V 88 T T			M	V			
79 H H N N N N N N N N N N N N N N N N N							
80 N N N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y							
81 Y Y E E E E E E E E E E E E E E E E E							Н
82 E 83 L 84 D G GG 85 E G GG 86 A P MM MM 87 M V 88 T T	80	N					N
83 L L 84 D G 85 E G 86 A P 87 M V 88 T T	81	Υ					Υ
83 L 84 D G 85 E G 86 A P 87 M V 88 T T	82						E E
84 D G G GG 85 E G G GG 86 A P MM 87 M V MM 88 T T	83	L					L
85 E G G MM 86 A P MM 87 M V MM 88 T T	84	D	G				GG
86 A P MM 87 M V MM 88 T T	85	E	G				GG
87 M V MM 88 T T	86	Α	Р				MM
88 T T	87	М	V				MM
	88						T
	89	L					L

Position		Di	verse Ar	nino Ac	id		Amino Acid Configuration With Less Tendency to Malignancy
90	Q						Q
91	R						R
92	R						R
93	>						V
94	Q						Q
95	Р						P
96	K	R					0
97	V						V N
98	N						V
99	٧						S
100	S						P
101	Р						S
102	S						К
103	K						K
104	K						G
105	G						Ρ
106	P						L .
107	L		 			├	Q
108	Q		 				н
109	Н					-	Н
110	H						N
111	N			-			L
112	<u> </u>		 				Ĺ
113	L	<u> </u>	 				V V
114 115	V C	ļ					Č .
			 	 		-	н
116	H	<u> </u>	-			-	v
117 118	T		 		-		T
119	D				 		D
120	F		 				F
121	Y		 				Y
122	P		 				Р
123	Ġ						G
124	S		 				S
125	1 1	 	†·				
126	Q	 		 		1	Q
127	V						V
128	R					T	R
129	W			<u> </u>			W
130	F						F
131	L						L
132	N						N
133	G						G
134	Q						Q
135	E						E
136	E						E
137	T						T
138	Α						Α
139	G						G
140	V						V
141	V					L	V
142	S						S
143	T						T
144	N						N
145	L	<u> </u>					L
146	1				ļ		
147	R		<u> </u>		ļ. <u></u>		R
148	N	<u></u>	1		l	1	N

Position		Div	verse A	mino Ac	id		Amino Acid Configuration With Less Tendency to Malignancy
149	G						G
150	D						D
151	w						W
152	T				<u> </u>		T
153	F						F
154					l	<u> </u>	Q
154	Q.			 		<u> </u>	i i
155					 	 	<u> L</u>
156	L						V
157	V				 		M
158	M						
159	L						L
160	E				L		E
161	M						M
162	T						Τ
163	Р						Р
164	Q						Q
165	Q				 		Q
166	G		ļ	 		 	G
100			 	 	 		D
167	D	ļ	<u> </u>	 	 		
168	V		ļ		ļ	ļ	V
169	Y		 	<u> </u>			Y
170		T					0
171	С					<u> </u>	C
172	Q						Q
173	V						V
174	E						E
175	H						Н
176	T				 		T
177	s		 	 	 	·	S
178	L	М			 		0
170		IVI		 	 	ļ	
179	D	L		ļ		 	D
180	S					ļ	S
181	P			ļ <u>.</u>			Р
182	V						V
183	T			<u> </u>		<u> </u>	T
184	V						V
185	Е					Γ -	E
186	W						W
187	K				1		K
188	A	ì					A
189	à	 	<u> </u>	 	 	† <i>-</i> -	Q
190	S	 	 	 	 	†	S
191	D	-	 	-	 		D
191		 	 		 	-	
192	S	<u> </u>		 	 	 	S
193	A	ļ		 	ļ	ļ	A
194	R	<u> </u>			ļ	ļ <u>.</u>	R
195	S				ļ		S
196	K			L			K
197	T						Ť
198	L						L
199	Т	l		1			Ť
200	G	T					Ġ
201	A	 	†	1	1	1	A
202	Ĝ	 	 	 	 	†	Ğ
203	G	 		 	 	 	G
204	F		 		 	 	<u> </u>
204	V			 	 	 	F
	Į V	i	ļ	L	ļ	ļ	V
200		a de la companya de	L				
206 207	L		ļ	L	ļ		L G

Position		Diverse Amino Ac	d Amino Acid Configuration With Less Tendency to Malignancy
208	L		L
209			
210			
211	С		C
212	G		G
213	V		V
214	G		G
215			
216	F		F
217	М		M
218	Н		H
219	R		R
220	R		R
221	S		S
222	К		K
223	К		K
224	V		V
225	Q		Q
226	R		R
227	G		G
228	S		S
229	A		A

Position	ו		Diverse	Amino	Acid		Amino Acid Configuration
_32	М	1	T^{-}		т-		With Less Tendency to Malignancy
_31	S	+		-+			M
_30	T W		+	\rightarrow			S
29	K						W
28	K						K
27	A	+ =					K
26		S					0
_26	<u> </u>						L L
_25	R					L	R
24	1						
23	P						P
_22	G						G
_21	D	G					0
_20	L						L
_19	R						R
_18	Α	V		$\overline{}$			
_17	A	 '	_		-		0
_16	1 7	+		+	+		Α
_15	T V					_	T
		-		-			V
14	T	_					T
_13	L						
_12	M						M
_11	L						L
10	Α_	S_					0
_9		М					0
8	L						L
_7	S						
_6	S	T					S
5	L	Р	S				0
4	L	V	+ -	+	┥	+	0
3	A	<u> </u>	+	╅┈┈	+		0
2	E	+	-				Α
1	G	+	╅		-	_	ΕΕ
1	R		-	+			G
2					 		R
- 4	D	+	-				D
3	Р	S		ļ.,			0
4	Р	<u> </u>					P
5	E						E
6	D						D
7	F						F
8	V						V
9	F	L	Y				0
10	Q						
11	F		i — —		 		Q
12	K			\vdash	 	+	F
13	A	G		 	+	+	K
14		М	 	 	 	 	0
15	c	- -	 	 	 	+	0 C
16	Y		 	├──	 	 	C
17	F			l			Υ
18	<u> </u>				 	 	F
19	N			 	 		
20	- 17				 		N
21	G						G
- 21	Ţ						T
22	E					1	E
23	L	R					0
24	V						V
25	R					 	V
26	G	L	Υ				R
27	V					 	0
					L	٠	V

28 S T	Position		Diverse Amino Acid					Amino Acid Configuration With Less Tendency to Malignancy
29	28	S	Т			T		vvidi Less Fendency to Malignancy
30	29	R				_	_	30()
31	30	H	S	T V				
332			1 <u> </u>		+		_	· · · · · · · · · · · · · · · · · · ·
33	32			+-		+		· · · · · · · · · · · · · · · · · · ·
34	33				+		+	
SS			+	+				
Signature Sign	35	 			-			
337								
38		+ 5	+			+		
39				- T	+			0
40	30	 ^				_	_	
41				+			_	
42 S 43 D 44 V 45 E G G 46 E V D 48 R 49 A 50 V 51 T 52 L P D 53 L Q D 54 G 55 L P D 56 L P D 57 A D Y 61 W 62 N 63 S 64 Q 65 K 66 D E 67 I V 68 L C D C C G R G F D C D D C C D C C	40						_	F
43 D 44 V 45 E G 46 E V 47 F Y 48 R 49 A 50 V 51 T 52 L P 53 L P 54 G 55 L P R 56 L P 57 A D S V 58 A 60 Y 61 W 62 N 63 S 64 Q 65 K 66 D E 66 D E 70 E G R 71 A D K 72 R 73 A A 74 A E S 75 L V 78 C C 80 C								D
44								S
44								
45					1			
46			G		 	1		
47 F Y 0 48 R R A 49 A A A 50 V V V 51 T T T 52 L P O O 53 L Q O O O 54 G G G G G 55 L P R O		E			+			
48 R 49 A 50 V 51 T 52 L F D 53 L Q Q 54 G 55 L P 56 L P 57 A D S 59 E Q 61 W W W 62 N N N 63 S S S 64 Q Q S 65 K K K 66 D E Q 65 K K K 64 Q Q K 65 K K K 66 D E Q 67 I V Q 68 L L Q 69 E E E 70 E G R <t< td=""><td></td><td>F</td><td></td><td></td><td>+</td><td> </td><td></td><td></td></t<>		F			+	 		
49 A 50 V 51 T 52 L P 53 L Q 54 G G 55 L P R 56 L P R 57 A D S 58 A A O 59 E E E 60 Y Y Y 61 W W W 62 N N N 63 S S S 64 Q Q S 65 K K K 66 D E G 67 I V O O 68 L L L 69 E G R E 71 A D K T O O 72 R T D D D D D D			 		+		+	
SO			 	+	+			
51 T T T T T T T T T T T T D		1-0-	+	 				
S2			+		+			
S3			 -	+ -	+			T
54 G		+						0
S55	53		Q	+	-			0
56 L P 0 57 A D S V 58 A A A A 59 E E E E 60 Y W W W W 61 W </td <td>54</td> <td></td> <td></td> <td></td> <td><u> </u></td> <td></td> <td></td> <td>G</td>	54				<u> </u>			G
Stock	55		P	R				0
ST	56							
Section Sect			D	S	V			
E		A						
61 W		E						F
61 W								Y
62 N		W						
63 S S S S S S S S S S S S S S S S S S S	62	N						
64 Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q	63	S		1				
65 K K	64	Q			1	+	+	3
66 D E O O O O O O O O O O O O O O O O O O		K		1	 	+		
67	66		F	 		+		
68	67		1 V		 	+		
69 E			 	 	 	-	+	
70 E G R 0 0 0 71 A D K T 0 0 0 72 R 73 A R 74 A E S 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			 	 	 	-	+	
71	70		G	P	 	 	+	
72 R R R 73 A R 74 A E S () 75 L V () 76 D D D D 77 R T () 78 V () 79 C SO R 81 H R 82 N R 83 Y N R 84 E Q O O O 85 A E O O			<u> </u>	1	-	 	+	
73 A A A A A A A A A A A A A A A A A A A			ا ت	 ^	 	+	+	
74 A E S 0 75 L V 0 76 D 0 77 R T 0 78 V 0 80 R 81 H 82 N 83 Y 84 E Q 0 85 L V 0 86 A E 0	73	- <u>'\</u>	 	 		 		R
74 A E S 0 75 L V 0 76 D 0 77 R T 0 78 V 0 79 C 0 80 R R R 81 H R R 82 N N N N N 83 Y Y Y 84 E Q 0 85 L V 0 86 A E C			-	-	 	ļ		
76 D O O O O O O O O O O O O O O O O O O	75	<u> </u>	<u> </u>			_		0
77 R T			_ <u> </u>	<u> </u>		 		0
78 V	77	<u> </u>				ļ		D
79 C V C C C C C C C C C C C C C C C C C	76	- K						()
80 R R R R H H H H H H H H H H H H H H H	78							- V
81 H H H H H H S2 N N N S3 Y Y S5 L V S6 A F C S S S S S S S S S S S S S S S S S S	79							C
82 N N N N N N N S Y Y S S C N O O O O O O O O O O O O O O O O O O	80	R						R
83 Y N Y Y Y S O O O O O O O O O O O O O O O O	81							H
84 E Q	82	_N						N
85 L V 0								V
85 L V 0	84		Q					1
			V					0
	86	Α	E	G			1	

1		Div	erse Ar	nino Aci	d	Amino Acid Configuration With Less Tendency to Malignancy
87	F	L	Y			0
88	R					R
89	G	Т				0
90		T				0
91	L					L C
92	Q					Q
93	R					R R
94	R					V V
95	V					E
96	Ε					P
97	Р					
98						V
99	V					T
100	_ _					
101			<u> </u>	-		S
102	S					P
103						S
104	S R		 	-		R
105	T		 _			T
106 107	E					E
107	A				+	A
109	- î - 					L L
110	N		 	-		N
111	H		 			Н
112	H					Н
113	N					N
114	L					L L
115	Ĺ					L
116		V	†			0
117	С					C
118	S					S
119	V					V
120	T		L			T
121	_ D_				ļ	D
122	F					F
123	Y		ļ	ļ		P
124	Р		<u> </u>		 	
125	Α	G	S			0
126	H	Q	 		 	
127	1		 	<u> </u>		K
128 129	K	<u> </u>	 	-		V
130	να	R	+	 		0
131	8	 ^	 	 		W
132	F		+	 		F
133	R	 	+	 		R
134	N		 		 	N .
135	D	 	1	†	 	D
136	Q		 	 		Q
137	E	 	1	1	 	E
138	E	 	†			E
139	Ŧ			1		T
140	A	T	1	i		0
141	G			1		G
142	V			i		V
143	٧	T				V
144	S					S
145	T		T	T		T

Position	Diverse Amino Acid				Amino Acid Configuration With Less Tendency to Malignancy		
146	Р	T		· т — — т — —	P		
147	L	+	 - - - - - - - - - 				
148	+ - -	+			<u> </u>		
149	R	+					
150	N	+	++		R		
					N N		
151	G			ļ	G		
152	D				D		
153	W				W		
154	T	<u> </u>			T		
155	F				F		
156	Q				Q		
157	1						
158	1		T		Ĺ		
159	TV	 	 	+ +	V		
160	М	_	 				
161	L	-	+		M		
101		┿					
162	E	ļ			E		
163	М	<u> </u>			M		
164	T	<u> </u>			T		
165	Р				P		
166	Q				Q		
167	Н	R		T	0		
168	G			 			
169	D	-		+	G		
170	V		 		D		
171	Y	 -			V		
172	T	 -	 		Υ		
173			 		T		
	C	<u> </u>			C		
174	Н				Н		
175	V				V		
176	E				E		
177	Н				Н		
178	Р				P		
179	S			1	S		
180	L			 			
181	Q		 	 	<u>L</u>		
182	N	s	 	 	Q		
183	P		 	 	0		
184			 	+	P		
185			 	 			
100	1			 	0		
186	V		 	ļl	V		
187	E				E		
188	W		<u> </u>		W		
189	R				R		
190	Α				Ä		
191	Q				Q		
192	S			 			
193	E			 	S		
194	s			 	E		
195	A			 	S		
196	Q			 	Α		
197	N	_		 	Q		
198	- IN	S		 	0		
190	K				K		
199	M				M		
200					L		
201	S	T			S		
202	G	T			S		
203	1	V					
204	G				0		
				<u> </u>	G		

Position		Di	verse Amino Acid	Amino Acid Configuration With Less Tendency to Malignancy			
205	G			G			
206	F	 		F			
207	·			V			
208	- i			Ĺ			
209	G			G			
210	- L	 		L			
211							
212	F			F			
213	Ė			L			
214	Ğ			G			
215	L	<u> </u>		L			
216	G			G			
217	L			L			
218	Ī						
219	1						
220	Н	R		0			
221	Н	Q		0			
222	R			Ř			
223	S			S			
224	Q	R		0			
225	K	1		K			
226	G	<u> </u>		G			
227	Р			P			
228	q			Q			
229	G	1		G			
230	Р			P			
231	Р			P			
232	Р			P			
233	Α			Α			
234	G			G			
235	L			Ĺ			
236	L			L			
237	Н			Н			

Position	Diverse Amino Acid						Amino Acid Configuration to Inhibit Metastases	Amino Acid Configuration to Inhibit Metastases
_29	М						M	M
_28	V						V	V
_27	Ċ						С	C
	Ĺ						L	L
_25	ĸ	R					0	0
-23	F	L	 				Ŏ	O O
_24							P	P
_23	Р		ļ				G	G
22	G							G
_21	G						9	S
_20	S						S	C
19	ပ		L				С	
_18	М						М	M
_17	Α	T					0	0
_16	Α	V					0	0
_15	L						L	L
_14	T	— —					T	Ť
_13	- 						V	V
		-	 	 			T	T
12	T		 	 				i i
_11	L	<u> </u>	<u> </u>	<u> </u>	<u> </u>		L	
_10	М						M	M
_9	V						V	V
_8	L						L L	L
_7	S						S	S
_6	S						S	S
_5	P		1				Р	P
_4	Ĺ		 -				L	L
_3	Ā						Ā	Α
2	î		 	_	 -	 	Ĺ	L
		S	1				0	0
11	A	-3-	 					G
1	G		ļ		-		G	
2	D	<u> </u>					D	D
3	T						Т	T
4	α	R					. 0	0
5	P						Р	P
6	R	l					R	R
7	F		1				F	F
8	L						L	L
9	E	K	W				0	0
10	Е	Q	Y				Ŏ	Ö
11	D.	Ğ	L	Р	S	V	Ö	Ŏ
12	K	T	1	 			Ö	Ŏ
13	F	Ġ	Н	R	S	Y	Ö	FF or GR
14	É	K	 	 ^	-	- '-		0
		 ^	 		 	 	<u> </u>	
15	C		 ,,-	<u> </u>		 	C	C
16	H	Q	Y			 	Q	YY
17	F	ļ	ļ			ļ	F	F
18	F		L				F	F
19	N	L	L				N	N
20	G						G	G
21	T	I				l	Ť	T
22	E	1	1	T	i		E	E
23	R	1	1			 	R	R
24	V	 	1	 	 		Ÿ	V
25	Q	P	 		-	 -		
25		R		 			0	0
26	F -	L	Υ	<u> </u>		 _	0	0
27	Ļ		 			L	<u>L</u>	<u>L</u>
28	О	E	Н	<u> </u>			0	<u>Q</u>
29	R		<u> </u>	ļ			R	R
30	C	G	Н	L	R	Υ	0	0

31	Position		D	iverse	Amino	Acid	v	Amino Acid Configuration to Inhibit Metastases	Amino Acid Configuration to Inhibit Metastases
32	31	F				T			
33		Н							
34	33	Н	N			\top			
35	34	Q					1		
36	35	E			\dashv				
37			_		+-				
38 A L V N O	37		 	NI NI	 				
39					- - -	+ '			0
R	30	+ ~	+-	- -		+			0
41			+ -						R
1			1 Y				11	0	
42									
43				<u></u> _ ·				S	
44	43	D							<u> </u>
45 G	44	V					\top		
## ## ## ## ## ## ## ## ## ## ## ## ##					+		++		
47 F Y 0 0 0 48 R R R R A B B E B B B B		1 -	+		 				G
48			 	+			+		E
R			 Y				$\perp \perp \downarrow$		0
A9	48		1	→	-			R	
SO							\perp T		
S1								V	
S2	51	T	1			1			
S3	52	Ε		1 -			1		
54 G G G G G G S S S R	53		1	 		_	 		
S5			 	+	+	+	+-+		
S66			+	+-	+	+	╀┷┷┼		
ST		+ -	 		+				R
Signature Sign	57		+	+	4			Р	Р
Section Sect		A_		<u>S</u>	V				
System	58		I E			<u></u>		0	
GO			L		1				
61 W			S	Y					
62 N N N N N N N N N N N N N N N N N N N		W							
63 S	62	N					 		
64 Q Q Q Q Q Q Q Q G G G G G G G G G G G	63			 	 	1	 		
65	64		 	† 	 	 	 		
Color			 	├	 		-		
D		<u> </u>	 	 	├	ļ			K
68			 	 	ļ	<u> </u>		D	
C				 	<u> </u>			0	
Fe				L	L	<u>_</u> .		L	
70 D Q R O O O O O O O O O O O O O O O O O O								E	
71 A E K R 0				R					
72 R Q R R R R R R R R R R R R R R R R Q		Α	Ε	K	R				
73 A G G N N N N N N O		R					_		
74 A E L Q R Q	73		G						
75 V V V V V V V V V V V V V V V V V V V	74		F	 	0	Р			
76 D D D D D D T					<u> </u>	-1			
77 N T O O O O O O O O O O O O O O O O O O	76		-		 -				v
78 V Y 0			 -			<u> </u>			D
79 C	79	- 17 -	! -					0	0
SO R R R R R R R R R	70							0	
81 H H H H H H H H H H H H H H H H H H H								C	Č
82 N H H H H H H H H H H H H H H H H H H		-к				T		R	B
83 Y N N N N S S S S S S S S S S S S S S S	81	_H_			7			н	· ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
84 G G G G G G G G G G G G G G G G G G G	82	N		7				N N	
64 G G G G G S S S S S S S S S S S S S S								· ·	N
85 A V O O O O O O O O O O O O O O O O O O	84	G							
86 G V 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	85		V						G
87 E () () () () () (88 S E E S S S S		G			+			0	0
88 S E E S S S	87	F			+			0	0
89 F S S		5 +				- $+$		Ε	Ε 7
F	89	-						S	S
		<u> </u>						F	F

Position	Diverse Amino Acid						Amino Acid Configuration to Inhibit Metastases	Amino Acid Configuration to Inhibit Metastases
90	T						T	Т
91	٧						V	V
92	Q						Q	Q
93	R						R	R
94	R						R	Ŕ
95	V			Ī			V	V
96	Ε	Н	Q	Y			0	0
97	P						P	P
98	E	K					0	0
99	>						V	V
100	Т						T	T
101	V						V	V
102	Υ						Y	Υ
103	Р			Ì			Р	Р
104	Α	S					0	0
105	K	_ <u>-</u> _	1				K	Κ
106	T					-	Ť	Ť
107	à	 	 	 	 		Q	Q
108	P	 	-	 	 		P	P
109			-	 	 		L L	L
110	Q	-	 	 	 		Q	Q
111	Н					 	н	H
112	Н		ļ			 	H	Н
				1	 	 -	N N	N N
113	N		 	<u> </u>			L	L
114	L	<u> </u>	 		 			1
115	L		-				L V	V
116	٧							
117	С		ļ	ļ	ļ	ļ	C	Ċ
118	S			ļ			S	S
119	V		<u> </u>			 	V	V
120	N	S		ļ	<u> </u>	<u> </u>	<u>O</u>	<u>O</u>
121	F					ļ	F	F
122	G			ļ			G	G
123	Υ						Y	Υ
124	P						Р	· P
125	G			<u></u>			G	G
126	S						S	S
127	1						1	1
128	Ε						E	E
129	V						V	V
130	R		L				R	R
131	W						W	W
132	F						F	F
133	L	R					O	0
134	N						N	N N
135	G						G	G
136	Q						Q	Q
137	E						E	E
138	E						E	E
139	K						К	ĸ
140	A	T					0	0
141	G						Ğ	Ğ
142	М	V					0	0
143	٧.					_	V	· · · · · · · · · · · · · · · · · · ·
144	S			l			S	S
145	T						T	T
146	Ġ						G	G
147	L						L L	L
148	ī			-			1	<u> </u>
					لــــا		<u> </u>	<u> </u>

Position	Diverse Amino Acid				Acid	Amino Acid Configuration to Inhibit Metastases	Amino Acid Configuration to Inhibit Metastases
149	н	Q				0	0
150	N					N	N
151	G					G	G
152	D					D	D
153	W					W	W
154	T					T	T
155	F					F	F
156	Q					Q	Q T
157	T					Ţ	L
158	L				<u></u>	L V	V
159	V						M
160	М				-+	M	Ľ
161	L_					L E	E
162	E					<u> </u>	T
163	T		-	-			0
164	F	<				0	P
165	P				_ +	P	0
166	a,	R			-+	0	S
167	S				\rightarrow	S G	G
168						E	E
169 170	E					V	V
171	Y					Y	Y
172	+					T	T
173	c					Ċ	С
174	a					Q	Q
175	v				_	V	V
176	Ē					E	E
177	H					Н	Н
178	P					P	Р
179	s	<u> </u>		_		S	S
180	L	V				0	0
181	М	Ŧ				Ŏ	0
182	S				Ī	S	S
183	Р					P	P
184	L					L	L
185	T					Т	T
186	V					V	V
187	E						E
188	W					W	W
189	R	S				0	0
190	Α				$oxed{oxed}$	Α	<u>A</u>
191	R					R	R
192	S		<u> </u>		\sqcup	S	s
193	E	ļ	<u> </u>	<u> </u>	\vdash	E	E
194	S		<u> </u>		 	S	S
195	Α	<u> </u>	<u> </u>			A	A
196	Q	<u> </u>	ļ		L	Q	Q
197	S		<u> </u>	<u> </u>	 	S	S
198	K	<u> </u>			 	К	К
199	М	L		ļ		M	M
200	L	<u> </u>	<u> </u>	ļ	\sqcup	<u> </u>	L L
201	S	<u> </u>	 		\vdash	S	S
202	G		<u> </u>	<u> </u>		G	G V
203	V		<u> </u>		 	V	V G
204 205	G		⊢			G	G
205	F		<u> </u>	 		F F	F
206	V	 	\vdash	 	\vdash	V V	- V
	<u>v_</u>	<u> </u>		L	L		

Position		Di	verse An	nino Acid		Amino Acid Configuration to Inhibit Metastases	Amino Acid Configuration to Inhibit Metastases
208	L					L	L
209	G					G	G
210	L					L	L
211	L					L	L
212	F				i i	F	F
213	L					L	Ļ
214	G					G	G
215	A					Α	A
216	G					G	G
217	L				1 -	L	L
218	F					F	F
219	i					1	I
220	Y					Y	Y
221	F					F	F
222	R					R	R
223	N					N	N
224	Q		i			Q	Q
225	K					К	K
226	G					G	G
227	Н					Н	Н
228	S					S	S
229	G					G	G
230	L					L	L
231	Р	Q				0	Q
232	Р					P	Р
233	R	Т				0	Q
234	G					Ğ	G
235	F					F	F
236	L					L	L
237	S					S	S